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Bone is in a constant state of remodeling, a process which was once attributed solely to 
osteoblasts and osteoclasts. Decades of research has identified many other populations of cells in 
the bone that participate and mediate skeletal homeostasis. Recently, osteal macrophages 
emerged as vital participants in skeletal remodeling and osseous repair. The exact mechanistic 
roles of these tissue-resident macrophages are currently unknown. Macrophages are highly 
plastic in response to their micro-environment and are typically classified as being pro- or anti-
inflammatory (pro-resolving) in nature. Given that inflammatory states result in decreased bone 
mass, proinflammatory macrophages may be negative regulators of bone turnover. Pro-resolving 
macrophages have been shown to release anabolic factors and present a potential target for 
therapeutic intervention in inflammation-induced bone loss and fracture healing. To better 
understand the role of macrophages in bone, an in vitro approach was used to study mechanisms 
of bone marrow macrophages. Additionally, macrophage functions in vivo were assessed in 
normal bone turnover and in oral osseous wound healing. 
The process of apoptotic cell clearance, termed efferocytosis, is mediated by pro-
resolving macrophages and may contribute to steady-state bone turnover as well as fracture 
healing. This process of efferocytosis by bone marrow macrophages was investigated in vitro. 
Interleukin-10, a pro-resolving cytokine, enhanced bone marrow macrophage efferocytosis of 
apoptotic bone marrow stromal cells (apBMSCs) in a phospho-STAT3 dependent manner. 
Additionally, macrophages engulfing apBMSCs secreted a unique profile of cytokines compared 
to macrophages engulfing apoptotic neutrophils. Macrophages displayed increased secretion of 
xiv 
 
monocyte chemotactic protein 1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) and 
transforming growth factor beta 1 (TGF-β1) in response to apBMSCs. This secreted protein 
profile suggests efferocytosis of apoptotic bone cells signals to recruit new osteoblast progenitors 
to repopulate apoptotic cells and initiate a new round of bone formation.   
Milk fat globule-EGF factor 8 (MFG-E8) is a secreted glycoprotein that facilitates the 
process of efferocytosis by acting as a bridge between apoptotic cells and phagocytes. The role 
of MFG-E8 in bone turnover was investigated. Mice deficient in MFG-E8 displayed decreased 
bone with age which correlated with an increased inflammatory phenotype and accumulations of 
apoptotic cells in the spleen. Increased inflammation leads to increased osteoclast differentiation 
and activation, resulting in decreased bone mass. MFG-E8 deficient mice displayed increased 
osteoclast numbers per bone surface. Intermittent daily parathyroid hormone (iPTH) 
administration is a known anabolic bone agent yet its use in patients is currently limited to cases 
of severe osteoporosis. MFG-E8 deficient mice responded to iPTH administration with a greater 
anabolic response than WT control mice. This suggests iPTH treatment may be beneficial in 
patients with inflammation-induced bone loss.   
Ineffective oral wound healing is detrimental to patients’ oral health related quality of 
life. Delineating the cellular mechanisms involved in optimal healing will elicit better 
approaches to treating patients with compromised healing. To study the role of phagocytic 
myeloid cells on oral wound healing, phagocytes were depleted with clodronate-loaded 
liposomes at the time of tooth extraction in mice. Depletion of macrophages and osteoclasts via 
clodronate treatment increased extraction socket bone fill 14 days after surgery, suggesting a 
crucial balance of macrophages and osteoclasts is necessary to promote effective healing.   
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A better understanding of the exact mechanisms by which macrophages mediate bone 
homeostasis and healing will lead to an expansion of pharmacologic targets for the treatment of 
























Myeloid cells in bone 
The skeleton provides structural support, is a reservoir of calcium, and supports the 
hematopoietic system. Given the importance of these functions, skeletal homeostasis is crucial to 
maintaining systemic homeostasis. The bone and bone marrow make up a highly dynamic organ, 
which is constantly in a state of turnover. Bone modeling and remodeling are dependent on 
traditional bone cells (osteoclasts, osteoblasts and osteocytes) as well as the hematopoietic cells 
of the bone marrow compartment which includes myeloid and lymphoid cells [1-3]. Cells of the 
myeloid lineage are important regulators of skeletal homeostasis and are the topic of this 
dissertation.   
The common myeloid progenitor cells give rise to megakaryocytes, erythrocytes, mast 
cells and myeloblasts. Myeloblasts then become basophils, neutrophils, eosinophils, or 
monocytes. Cells originating from monocytes include tissue resident macrophages, macrophages 
of the immune response and dendritic cells. Macrophages, Greek for “big eaters,” are phagocytic 
cells with pro- and anti-inflammatory functions. They are recruited to sites of infections and 
inflammation and aid in the process of tissue repair. The bone and bone marrow consist of 
various macrophages occupying specific niches including: hematopoietic stem cell niche 
macrophages, erythroid island macrophages, osteal macrophages, and osteoclasts. The exact 
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mechanisms by which myeloid cells regulate bone turnover are elusive and are currently being 
investigated.  
The work presented in this dissertation focuses on myeloid cell contributions to bone 
homeostasis and repair. Chapter 2 presents an in depth literature review on the role of 
macrophages in skeletal health with a focus on therapeutic options available and how they alter 
myeloid/macrophage populations in bone. In addition, Chapter 2 introduces a major function of 
macrophages: apoptotic cell clearance. This process has been termed efferocytosis, from the 
Latin root “efferre” meaning “to take to the grave” or “to bury” [4]. Efferocytosis is a highly 
regulated process and is crucial to maintaining tissue homeostasis. Accumulations of apoptotic 
cells lead to deleterious effects and are a hallmark of autoimmune diseases, such as systemic 
lupus erythematous. The role of macrophage efferocytosis in bone is underappreciated and is 
investigated in Chapters 3 and 4.   
Macrophages act differently according to their environment. Tissue resident macrophages 
in the lung will see and respond to different stimuli than those in the liver, for example. Bone 
marrow macrophage efferocytosis of osteoblastic cells was investigated to determine what 
factors regulate efferocytosis in the bone and how the macrophages respond to those cues. It is 
hypothesized that due to the pro-resolving nature of the process of efferocytosis, macrophages 
may positively regulate bone turnover by engulfing apoptotic bone cells and releasing factors to 
help recruit a new set of progenitor populations. The link between macrophage efferocytosis and 
bone turnover is currently being investigated. Chapter 3 highlights a series of in vitro 
experiments which investigate mediators of efferocytosis as well as specific macrophage 
responses to apoptotic bone cell “meals.” The findings of this chapter demonstrate that bone 
marrow derived macrophages secrete monocyte chemoattractant protein-1 (MCP-1) and 
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transforming growth factor beta 1 (TGF-β1) in response to apoptotic bone marrow stromal cells 
but not apoptotic neutrophils. MCP-1 and TGF-β1 are known monocyte and mesenchymal cell 
recruitment factors, respectively. Given the specificity of the secretion of these factors in 
response to engulfing apoptotic bone cells, these data suggest one function of macrophages in 
bone is to support the repopulation of the bone forming unit as cells undergo apoptosis. These 
findings contribute to the growing literature on the role of macrophages in bone.  
As mentioned above, efferocytosis is a highly coordinated process. It requires the 
recognition of apoptotic cells by phagocytes, a rearrangement of cytoskeletal elements in the 
phagocytes to surround and engulf the apoptotic cell, and the processing of the dead cell 
internally [5-7]. Milk fat globule epidermal growth factor 8 (MFG-E8) is a secreted glycoprotein 
that binds to phosphatidylserine exposed on the outer membrane of cells undergoing cell death in 
addition to binding the αvβ3/αvβ5 integrin expressed on the macrophage [8]. MFG-E8 deficiency 
leads to various alterations in tissue homeostasis, healing, and inflammatory response [9-13]. 
Table 1.1 details some of the phenotypes seen in mice lacking functional MFG-E8. In addition 
to the findings reported in the table, MFG-E8 has recently been identified as a positive regulator 
of bone turnover [14-16], but the mechanistic role, specifically regarding efferocytosis, has not 
been described. In chapter 4, the contributions of MFG-E8 to bone turnover were investigated in 
a mouse model of MFG-E8 deficiency. Mice with the deficiency had inflammatory-like 
phenotypes, increased accumulations of apoptotic cells in the spleen, and decreased bone with 
age. A known anabolic bone therapeutic agent (teriparatide, hPTH 1-34) was administered to 
MFG-E8 deficient mice to investigate the ability to rescue the phenotype. Interestingly, treatment 
with intermittent PTH caused an anabolic response in the MFG-E8 deficient mice that exceeded 
the anabolic changes seen in WT control mice. The data presented in chapter four expands our 
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understanding of factors that regulate bone turnover and gives further insight on the potential use 
of anabolic bone agents in inflammation-induced bone loss.      
In addition to investigating macrophages in homeostatic bone turnover, the role of bone 
macrophages in healing was investigated. There are various tools to deplete different cell types 
and assess the resulting phenotype. Chapter 5 focuses on the results of depleting phagocytic cells 
using liposomes loaded with clodronate. When engulfed, liposomes containing clodronate are 
metabolized to a toxic byproduct which leads to death of the phagocyte. The effect of depleting 
phagocytic cells via clodronate-loaded liposomes on normal bone turnover was investigated. 
Additionally, the role of these phagocytes in facilitating oral osseous wound healing was 
investigated using a tooth extraction protocol. Understanding the contributions of specific cells 
to the healing process will aid in the design of targeted therapeutics for oral osseous wound 
healing.  
The work presented in this dissertation highlights various models to study myeloid cell 
contributions to bone homeostasis and healing and provides  a better understanding of the 
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MACROPHAGES AND SKELETAL HEALTH 
 
Introduction 
The skeleton is a complex organ that provides structural support, protection of the body’s 
internal organs, houses the hematopoietic system, and serves as a reservoir of calcium. Bone is in 
a constant state of turnover which is balanced by bone formation and resorption; processes which 
are controlled by the activity of bone resident cells: osteoblasts, osteocytes, and osteoclasts. The 
bone and bone marrow consist of several other cells that play crucial supportive roles in the 
process of homeostatic bone turnover including, but not limited to, T  and B cells, mast cells, and 
monocytes/macrophages [1-5]. An imbalance in the bone remodeling process due to alterations 
in osteoblast or osteoclast activity can lead to elevated bone mass (increased osteoblast activity 
or decreased osteoclast activity) or decreased bone mass (decreased osteoblast activity or 
increased osteoclast activity).  
Approximately 44 million Americans have low bone mass, placing them at a high risk of 
developing osteoporosis, a disease affecting over 10 million Americans [6]. Loss of bone mass 
leads to increased fracture risk, which has a high rate of morbidity and mortality in the elderly 
population [7]. Osteoporosis-related fractures often lead to hospitalizations and nursing home 
placement, decreasing the patient’s quality of life and posing a large burden on healthcare 
systems. Bone loss leading to osteoporosis has been widely studied in the context of menopause 
and estrogen deficiency and is associated with an increase in osteoclast activity relative to 
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osteoblast activity [8]. Estrogen does not likely mediate osteoclast activity directly, however the 
withdrawal of estrogen results in the increased production of inflammatory cytokines [9]. These 
inflammatory mediators are major contributors in the increased osteoclast activity seen in 
menopause-associated bone loss. An early study by Horton et. al demonstrated that osteoclasts 
which were exposed to activated leukocyte cell supernatant increased osteoclast number and 
activity [10]. This finding led to a large body of research investigating various proinflammatory 
factors and their role in osteoclast stimulation. Some of these proinflammatory cytokines which 
have been shown to increase osteoclastic differentiation and activity include tumor necrosis 
factor alpha (TNF-α) [11-15], prostaglandins [16], interleukin-1 (IL-1) [11, 12, 17-20], IL-6 [21-
23], IL-11[24, 25], IL-15 [26], and IL-17 [27]. The increase in osteoclast differentiation is in 
large part due to an increase in receptor activator of nuclear factor kappa-B ligand (RANKL) 
production in target cells. RANKL binds to RANK on pre-osteoclasts and induces 
differentiation. However, it has been shown that TNF-α can induce osteoclast differentiation 
when RANKL levels are lower than necessary for osteoclastogenesis [28]. 
Increased proinflammatory cytokine production is not only seen in during estrogen 
withdrawal but is also associated with various inflammatory diseases. Systemic and/or local bone 
loss is often seen in patients with inflammatory diseases [29, 30] including systemic lupus 
erythematous [31], rheumatoid arthritis [32-34], cystic fibrosis [35], chronic obstructive 
pulmonary disease [36], inflammatory bowel disease (IBD) [37, 38], and periodontal disease 
[39].  The inflammatory process is a complex response which is mediated by various cells of the 
innate and adaptive immune systems. The direct effect of inflammatory cytokines on osteoclast 
activity has been well studied, and the cells mediating these effects are becoming more 
appreciated for their roles in bone homeostasis. 
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The focus of this review is the role of immune cells, specifically monocyte/macrophages, 
on the maintenance of bone and their contributions to bone disease.  Additionally, the therapeutic 
potential of targeting osteal macrophages in bone-related diseases will be highlighted.  
 
Translating traditional macrophage actions to their roles in bone 
 Macrophages, Greek for “big eaters,” were first described by Elie Metchnikoff over 100 
years ago and are traditionally known for their phagocytic roles in inflammation and immunity 
[40]. They are a heterogeneous population of cells with multiple phenotypes whose function is 
based on surrounding environmental cues. These macrophage phenotypes, commonly referred to 
as polarizations, were once considered to be distinct populations which could be divided into M1 
(classically activated) or M2 (alternatively activated) subsets [41, 42]. A large body of research 
has focused on defining these populations of cells, and it has become clear that macrophage 
polarization cannot simply be divided into two unique populations, but rather consists of a 
spectrum of phenotypes [43-45]. A collaboration between multiple groups has worked together 
to create a set of standards which outline the sources of macrophages, activators of macrophages, 
and defines various markers of macrophage activation [46]. Due to the heterogeneity of 
macrophages, the original definitions of these cells are no longer categorized as M1 or M2. Not 
only have subcategories been identified such as M2a, M2b, and M2c [47], but the original two 
designations are currently referred to as “M1-like” and “M2-like,” due to the overlap of the 
expression of markers. 
M1-like or classically-activated macrophages are defined for their role in mediating an 
inflammatory response. They polarize toward the M1 phenotype in response to inflammatory 
cytokines released from Th1 cells, such as IL-1 and IL-6. M2-like macrophages are present 
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during the resolution phase of inflammation and are responsible for anti-inflammatory cytokine 
production and enhanced clearance of apoptotic cells, termed efferocytosis [48-50]. Exposure to 
anti-inflammatory cytokines IL-4, IL-12 and IL-10 leads to M2-like macrophage polarization 
[51], and increased apoptotic cell clearance [52-54].  
Tissue-resident macrophages are found in nearly all tissues other than hyaline cartilage, 
and play additional roles other than immunity and inflammation, including supporting tissue 
homeostasis, clearance of debris and tissue repair [55-58]. The differentiation and maintenance 
of tissue-resident macrophages is unique compared to that of adult hematopoietic cell renewal 
via hematopoietic stem cells (HSCs). It has recently been shown that many adult tissue-resident 
macrophages differentiate from a Tie2+ cellular pathway which leads to yolk sac-derived 
myeloid progenitors that develop prior to the appearance of HSCs [59, 60]. This distinction is 
important because the unique origin and differentiation of tissue macrophages has significant 
relevance to disease. 
Tissue-resident macrophages perform specific functions based on the tissue in which they 
reside. For example, the lung consists of alveolar macrophages which survey for inhaled 
pathogens and regulate homeostasis of the tissue through surfactant clearance [61-63]. Kupffer 
cells in the liver participate in the clearance of aged erythrocytes [64].  Figure 2.1A depicts 
several of the tissue-resident macrophages. Of interest to this review, the bone and bone marrow 
microenvironment maintains several tissue-resident macrophage populations, each with distinct 
locations and functions.  
The bone and bone marrow consist of three known distinct macrophage populations: 
bone marrow macrophages (erythroid island macrophages and hematopoietic stem cell 
macrophages), osteoclasts, and a recently defined population of macrophages termed osteal 
14 
 
macrophages or “osteomacs” [3] (Figure 2.1B). Historically, bone marrow macrophages have 
been studied in the context of erythropoiesis [65, 66] and hematopoietic stem cell niche 
maintenance [67, 68]. Osteoclasts have long been identified as the tissue-resident macrophages 
in bone, although they now share this designation with the other bone macrophage populations. 
Osteoclasts differentiate down the monocyte lineage, and fuse to become multinucleated  
tartrate-resistant acid phosphatase (TRAP)-positive cells. Osteal macrophages are a distinct 
subset of bone macrophages located in close proximity to the bone surface and are F4/80-
positive (Figure 2.2) [69] and TRAP-negative [3]. These osteal macrophages were characterized 
and found frequently located next to active bone forming osteoblasts. The majority of osteoblasts 
on the inner surface of cortical bone are covered in F4/80+, CD68+, Mac-3+, TRAP– 
macrophages [70]. Table 2.1 details the known markers and functions of the four macrophages 
present in bone. The specific myeloid progenitors and functional roles of the osteal macrophage 
are currently under investigation. The proximity to the bone forming unit suggests that they 
communicate with bone resident cells and play a supportive role in the bone remodeling process. 
To investigate the functional role of osteal macrophages, several in vitro assays have 
identified a supportive role for macrophages in mediating bone formation. An early study by 
Champagne et al. [71] demonstrated that human and murine macrophages produce bone 
morphogenetic proteins (BMPs), specifically BMP-2 and BMP-6. Mesenchymal stem cells 
(MSCs) (osteoblast progenitor cells) grown in conditioned media from J774A.1 macrophage 
cells displayed increased osteoblast differentiation gene expression, and treatment of 
macrophages with anti-BMP-2 prevented the pro-osteogenic effect [71]. Primary cell cultures 
which are used to assess osteoblastogenesis and mineralization consist of a heterogeneous 
population of cells. To measure the contribution of macrophages in these cultures, primary 
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calvarial osteoblast cultures were sorted for macrophage markers and found to consist of 11% to 
17% F4/80+ macrophages [3]. When macrophages were depleted from cultures using a magnetic 
sorting technique, mineralization and osteoblastic differentiation gene expression was 
significantly reduced [3]. Nicolaidou et al. [72] also found that monocytes/macrophages induce 
human MSC differentiation into osteoblasts and increase mineralization. Increased oncostatin M 
(OSM) production by monocytes led to upregulation of signal transducer and activator of 
transcription 3 (STAT3) in MSCs and enhanced differentiation. Neutralizing antibody to OSM 
decreased MSC differentiation into osteoblasts [72]. These findings were supported by a study 
showing that OSM produced by activated circulating CD14+ or bone marrow CD11b+ 
monocytes/macrophages induced osteoblast differentiation and matrix mineralization from 
human mesenchymal stem cells [73]. Treatment of MSCs with recombinant OSM also 
stimulated osteoblast differentiation [74]. 
These in vitro data support the hypothesis that macrophages are important in mediating 
osteoblastic differentiation and mineralization. In vivo macrophage ablation models further 
support these findings. The macrophage Fas-induced apoptosis (MAFIA) mouse model results in 
depletion of colony-stimulating factor-1 receptor (c-Fms) positive myeloid lineage cells upon 
administration of AP20187 [75, 76]. MAFIA mice administered AP20187 displayed markedly 
reduced osteoblast lining bone surfaces, decreased bone formation, and an overall reduction in 
bone volume [3, 77, 78]. Another method to deplete macrophages is the lysozyme-M (LysM) 
driven cre model. LysM is expressed in cells of the myeloid lineage [79] and when LysMcre 
mice were crossed with R26RDTA mice, LysM expressing cells including monocytes and 
macrophages were depleted [80]. Macrophage depletion using the LysMcre-DTA model led to 
decreased bone growth in young mice and osteoporosis in skeletally mature mice [80]. 
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 Given that osteoclasts and macrophages differentiate from the monocytic lineage, 
macrophage ablation experiments targeting either c-Fms or LysM should also affect osteoclasts. 
In the MAFIA mouse model using c-fms driven macrophage depletion, Cho et al. [78] 
demonstrated that the dosing regimen of AP20187 used successfully depleted macrophage 
populations without altering the number of osteoclasts per bone surface in vivo. Conversely, Vi 
et al. [80] demonstrated in the LysM model of macrophage depletion that osteoclasts were 
present in macrophage depleted mice, however they were reduced and less active. In vitro assays 
of osteoclast resorptive potential showed that osteoclasts from the LysM mice were still 
functional at resorbing bone. It is important, therefore, that models of macrophages depletion 
used to investigate bone phenotypes, should consider the potential osteoclast effects.  Taken 
together, these studies show that macrophages are important and necessary contributors to the 
bone modeling and remodeling process. Their mechanistic roles are under ongoing investigation. 
 Macrophages are well known for their role as professional phagocytes.  As mentioned 
previously, macrophages can be polarized based on the environment in which they reside. M1-
like macrophages participate in the inflammatory response and are primed by proinflammatory 
cytokines. Proinflammatory cytokines enhance osteoclast differentiation and resorption by 
upregulation of RANKL, resulting in low bone mass phenotypes. M2-like macrophages, on the 
other hand, are considered resolution phase macrophages and participate in the clearance of 
apoptotic cells, termed efferocytosis, following an inflammatory milieu [50, 81-83]. Under 
normal conditions, approximately one million cells in the body become apoptotic each second, 
and the effective clearance of these apoptotic cells is crucial to prevent an abnormal 
inflammatory response or systemic autoimmunity [84-86]. The bone marrow is a complex organ 
that consists of millions of cells which undergo turnover daily, resulting in a large amount of 
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apoptotic cells to be cleared. To maintain homeostasis, these cells must be rapidly and effectively 
cleared. In regards to the bone forming unit cells, osteoblasts have three fates: they become 
bone-lining cells, osteocytes or undergo apoptosis. Of the osteoblasts initially at remodeling 
sites, more than 50% are thought to undergo apoptosis [87]. The role of pro-resolving 
macrophages and the process of efferocytosis have recently surfaced in bone, and studies 
investigating apoptotic cell clearance may lead to a better understanding of the functional role of 
osteal macrophages.  
Macrophage polarization is of interest in the context of bone and may provide clues into 
the functional role macrophages play in skeletal homeostasis [88]. Macrophage expression of the 
osteoinductive factors BMP-2 and BMP-6 was reduced when macrophages were stimulated with 
lipopolysaccharide (LPS), a known proinflammatory M1 macrophage mediator [71]. 
Conditioned media from macrophages treated with LPS were unable to produce the stimulatory 
effect on MSC differentiation into osteoblasts [71]. This suggests that proinflammatory 
mediators may result in reduced bone phenotypes by altering macrophage expression of 
osteoinductive factors. Furthermore, conditioned media from macrophages treated with IL-4 and 
M-CSF (M2 activation) increased osteoblast maturation from MSCs, whereas macrophages 
treated with granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma 
and LPS (M1 activation) did not [74]. These findings support alternatively activated 
macrophages as mediators of bone homeostasis.  
The functional role of macrophages and the participation of efferocytosis in bone 
remodeling is further supported by macrophage ablation experiments.  The depletion of myeloid 
lineage cells via the MAFIA mouse model resulted in decreased F4/80+ cells, CD68+ cells, and 
reduced bone mass [78]. In the same study, clodronate-loaded liposomes were administered to 
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mice to deplete mature macrophages with phagocytic capacity. This method of macrophage 
ablation also led to a decrease in F4/80+ cells, however, CD68+ and CD163+ cells were 
reciprocally increased as was bone mass. CD68+ and CD163+ cells are mature phagocytic 
macrophages that participate in the process of efferocytosis.  It is hypothesized that these cells 
were increased after administration of the clodronate liposomes in a positive feedback 
mechanism [78]. To further support the hypothesis that the increase in CD68+ cells in the 
clodronate model also coincided with increased apoptotic cell clearance, TUNEL staining 
verified a reduction in apoptotic cells in the clodronate-treated mice compared to the MAFIA 
mouse model. Furthermore, clodronate-treated mice displayed increased whole bone marrow 
gene expression of M2-related genes and no change in M1-related genes [78]. Furthermore, the 
clodronate-liposome treatment resulted in increased expression of osteogenic genes including 
Wnt-10b and TGF-β1. The increased bone mass in the clodronate model of macrophage 
depletion suggests a correlation between the process of apoptotic cell clearance and bone 
turnover.   
 During programmed cell death, cells begin to expose phosphatidylserine (PS) on their 
outer membrane. Phagocytic cell receptors recognize PS on apoptotic cells which leads to 
signaling and initiates engulfment of the apoptotic cell [83, 89]. Milk fat globule-epidermal 
growth factor 8 (MFG-E8), also known as lactadherin, is a secreted protein which forms a bridge 
between PS on the apoptotic cell and the vitronectin receptor (αvβ3 integrin) on the phagocyte. 
MFG-E8 knockout mice displayed decreased bone mass and accelerated bone loss due to 
ovariectomy [90]. Cell autonomous studies revealed MFG-E8 knockout osteoblasts mice had 
decreased mineralization and knockout osteoclasts were more active. The phagocytic capacity of 
bone marrow macrophages were not assessed in this study but were shown to have decreased 
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phagocytosis by others [91]. These data suggest that MFG-E8 may have direct roles in osteoblast 
and osteoclast activity, but MFG-E8-mediated efferocytosis by macrophages may also contribute 
to the low bone mass phenotype seen in these mice. Further investigation into the direct effects 
of efferocytosis on bone turnover is important in better delineating the mechanistic roles of 
macrophages in mediating bone homeostasis.  
Recent studies have begun to define the role macrophage-mediated clearance of apoptotic 
bone cells on bone turnover [54, 92]. Live cell imaging shows that bone marrow derived 
macrophages readily engulf apoptotic MC3T3 (osteoblastic) cells, resulting in complete 
clearance [92]. Similarly, bone marrow macrophages engulf apoptotic primary bone marrow 
stromal cells as shown using flow cytometric analysis in conjunction with ImageStream analysis 
(Figure 2.3). IL-10 was investigated as a mediator of apoptotic bone marrow stromal cell 
clearance [54]. Bone marrow derived macrophages primed with IL-10 displayed enhanced 
efferocytosis of apoptotic bone cells and mimicked an M2-like phenotype (CD206+). Following 
engulfment of apoptotic bone marrow stromal cells or MC3T3 cells, macrophages secreted the 
osteogenic molecule TGF-β1 and monocyte cell attractant chemokine (C-C motif) ligand 2 [54]. 
These factors were upregulated in comparison to the engulfment of apoptotic neutrophils, 
suggesting that efferocytosis of apoptotic bone cells leads to a distinct expression profile which 
may aid in the recruitment of progenitor cells to repopulate the dead/dying cell populations. The 
exact mechanistic role of osteal macrophages in supporting bone turnover is currently being 






Macrophages in bone disease 
Tissue homeostasis requires a tightly organized system of various cell types working 
together to maintain balance. If the balance is disrupted, the progression of aberrant disease 
states may persist. While a direct link between macrophage function and bone-related diseases 
has not been thoroughly investigated, there are clear macrophage phenotypes which present in 
various disease states. As mentioned previously, proinflammatory mediators enhance 
osteoclastogenesis and activity in part due to upregulation of RANKL. Increased inflammatory 
cytokines have been associated with post-menopausal osteoporosis, yet the in vivo 
characterization of bone marrow or osteal macrophage phenotypes under these conditions is not 
known. It may be speculated that increased inflammatory cytokines encourages a shift in 
macrophage phenotypes toward M1-like. The exact role of macrophages in osteoporosis is as yet 
unknown.  
 During aging, repair processes, including fracture repair, often become less efficient [93, 
94]. The cellular processes which are impaired in aging are under investigation. When bone 
marrow from 4 week old mice was transplanted into 12 month old mice, fracture healing was 
enhanced in the older mice [95]. The positive effects were attributed to the young inflammatory 
cells aiding in the repair processes. Additionally, parabiosis experiments showed that youthful 
circulating factors mediated repair processes in aged mice [96]. While the bone marrow 
transplants and parabiosis studies result in the exchange of a heterogeneous population of cells, 
macrophages may play a contributory role. In fact, in other tissues, macrophages have been 
shown to be less effective at tissue repair with age [97]. Aging also coincides with an increase in 




Rheumatoid arthritis displays local and systemic bone loss and is associated with joint 
destruction. The exact pathogenesis of rheumatoid arthritis is unknown, yet macrophage 
activation contributes greatly to its presentation. Macrophages have been shown to be an 
important source of proinflammatory cytokines such as IL-1β, IL-6, TNF-α and GM-CSF locally 
and systemically [104, 105]. The increased proinflammatory cytokines enhance osteoclast 
differentiation and activity via upregulation of RANKL, and leads to bone destruction. 
Macrophages and their byproducts have become candidate targets in the treatment of rheumatoid 
arthritis, and include anti-TNF antibodies and the inhibition of c-Fms  [106]. However, it is 
proposed that specifically targeting proinflammatory M1-like macrophages may result in more 
positive results than depletion of all macrophages [107].  Additionally, mice deficient in MFG-
E8, a protein that mediates apoptotic cell clearance, have exacerbated rheumatoid arthritis 
presentation [108]. While macrophages were not characterized in this study, the known role of 
MFG-E8 in M2-mediated clearance of apoptotic cells suggests that M2 macrophages may be 
important in preventing rheumatoid arthritis symptoms by aiding in inflammation resolution and 
debris clearance.  
Osteonecrosis of the jaw (ONJ) presents as exposed necrotic bone in the oral cavity. ONJ 
is often associated with high-dose intravenous antiresorptive therapies used in patients with 
metastatic bone disease [109]. The exact etiology is not known for ONJ, but inflammatory 
macrophages have recently been shown to play a role [110]. Increased IL-17 correlated with an 
increase in M1 to M2 macrophage ratio in patients ONJ lesions. Adoptive transfer of M2 
macrophages expanded ex vivo decreased ONJ severity, IL-17 production and M1 to M2 ratio in 
a mouse model for ONJ [110]. Neutralizing antibody to IL-17 also decreased the M1 to M2 ratio 
and disease prevalence in mice. These data suggest that M1 macrophages correlate with ONJ 
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disease presentation and severity, and targeting M1 macrophage activation by IL-17 may serve 
as a potential therapeutic for patient at risk for developing ONJ lesions.    
 
Macrophages in bone repair 
 Macrophages function to maintain normal tissue homeostasis and play a crucial role in 
tissue damage repair. This is also true in osseous wound healing. Following a fracture, bone is 
regenerated to fill in the fracture space to restore form and function. After tissue injury, damaged 
tissue and apoptotic cells are abundant and must be cleared to allow for proper modeling of the 
site. Bone healing generally involves five stages: the inflammatory response, soft callus 
formation, hard callus formation, union, and bone remodeling (reviewed in [111]). The initial 
inflammatory response provides an influx of cells, including macrophages. Macrophages are 
important in the early stages of bone healing, yet their more crucial role has been shown to be 
during the subsequent anabolic steps in bone repair. The MAFIA mouse model was used to 
assess the macrophage contribution to healing via intramembranous ossification or endochondral 
ossification [112, 113]. In both models of repair, macrophage depletion at the time of injury 
resulted in substantially reduced collagen type-I deposition and bone mineralization leading to 
impaired bone repair. Vi et al. [80] utilized the macrophage depletion LysMcre-DTA model and 
similarly found that macrophage depletion significantly impaired tibial fracture healing. To 
better assess the role of macrophages in the later stages of fracture healing, the MAFIA mouse 
model was also utilized to deplete macrophages after the initial inflammatory events and prior to 
the anabolic phase. Interestingly, macrophage depletion during this phase also led to decreased 
healing [112, 113]. These data suggest that macrophages are important during various stages of 
bone repair and are necessary for proper healing. Additionally, this may implicate different 
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macrophage phenotypes during healing as the initial inflammatory macrophages may be distinct 
from those present during the anabolic phase. Indeed, inflammatory and osteal macrophages 
predominate in different locations within fracture sites, further supporting separate functional 
roles [112, 113]. Clearly, macrophages present a possible therapeutic target for enhancing 
fracture healing. 
 The mechanisms by which macrophages exert their positive effects on bone formation are 
not clearly understood. Guihard et al. [114] expanded on their in vitro findings that OSM 
produced by macrophages supports osteoblastic mineralization by investigating signaling during 
tibial injury healing. They found that OSM expression was increased during the inflammatory 
phase of healing and that macrophage depletion via the clodronate-loaded liposome model led to 
decreased OSM expression [114]. Furthermore, OSM and OSM receptor null mice had fewer 
osteoblasts and less bone formation within the injury site. These data support OSM as an 
important pro-anabolic molecule in the healing of bone and a potential target for fracture healing 
therapeutics. Macrophages can secrete other osteoinductive factors (TGF-β1, BMP-2, BMP-4, 
BMP-6), which have only begun to be explored in the context of macrophage-mediated osseous 
wound healing.  Macrophages are implicated in the heterotopic ossification that occurs following 
tissue injury due to trauma and burns playing an important role as immune effector cells in 
ectopic bone formation [115]. One study demonstrated a role for macrophage derived BMP4 in a 
genetic mouse model where soft tissue injuries led to bone with marrow in extraskeletal tissues 
[116]. As macrophages are typically at the interface of the adaptive and innate immune systems 
and have both inflammatory and anti-inflammatory phenotypes, their ability to orchestrate 




Current osteoporosis therapies and how they affect macrophages 
 Antiresorptives are commonly used therapeutics to combat the bone loss associated with 
osteoporosis secondary to menopause or systemic inflammation as well as to treat metastatic 
bone diseases and hypercalcemia. Broadly, antiresorptives inhibit osteoclast activity, either 
through targeting key differentiation steps or preventing mechanisms which osteoclasts use to 
adhere to and resorb bone. The most common category of antiresorptives used clinically are the 
bisphosphonates.  
Bisphosphonates attach to hydroxyapatite in bone and are incorporated into osseous 
surfaces. Depending on the structure of the bisphosphonate, as osteoclasts resorb bone that has 
incorporated bisphosphonates, the bisphosphonates inhibit osteoclast activity or induce 
apoptosis. Nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase leading 
to impaired ability to adhere to bone and produce protons necessary for resorption [117, 118]. 
Simple bisphosphonates on the other hand do not contain nitrogen. These molecules are 
metabolized by osteoclasts to a toxic analogue of adenosine triphosphate (ATP) resulting in 
osteoclast apoptosis [119, 120]. The effects of bisphosphonates on osteoclasts have been widely 
studied, yet the effects on macrophages are just becoming apparent [121]. The phagocytic nature 
of macrophages makes them susceptible to uptake of bisphosphonates [122, 123]. Macrophages 
treated in culture with nitrogen-containing bisphosphonates versus simple bisphosphonates 
responded differently. Simple bisphosphonates reduced inflammatory cytokine (IL-1β, IL-6, 
nitric oxide) production by macrophages whereas nitrogen-containing bisphosphonates enhanced 
IL-1β and IL-6 production [124, 125]. These results indicate that bisphosphonates alter cytokine 
release profiles by macrophages and may therefore alter their interactions with bone cells. 
Bisphosphonates have also been shown to decrease osteoclastogenesis [126, 127]. Osteoclast 
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precursors are of the monocyte-macrophage lineage and may also be altered in the process of 
reduced osteoclastogenesis. The exact alterations in these cell populations are not appreciated, 
but further understanding may allow for better tailored osteoporosis therapies. 
Denosumab is also an antiresorptive, yet its mechanism of action is different than 
bisphosphonates. Denosumab is a human monoclonal antibody that binds to RANKL which 
selectively inhibits osteoclastogenesis. It is FDA approved for the treatment of postmenopausal 
osteoporosis for women with high or increased fracture risk [128]. Due to its long half-life, 
administration of denosumab for the treatment of osteoporosis is once every six months, making 
it more manageable than daily or weekly bisphosphonates [129]. Monocytes and macrophages 
express RANK, the receptor for RANKL. Interestingly, studies have shown that denosumab does 
not alter the functions of monocytes [130, 131]. Additionally, denosumab was not shown to alter 
differentiation or viability of macrophages from monocytes [132].  Reports of severe infections 
as low incidence adverse events in cancer patients taking denosumab have not surfaced in 
osteoporosis patients, yet raise the potential for high doses impacting aspects of the host response 
[133]. While studies do not imply that denosumab changes macrophage differentiation, further 
exploration of macrophage responses to RANKL inhibitors seems prudent. 
Odanacatib is a cathepsin K inhibitor, a key enzyme utilized by osteoclasts to break down 
bone. Recently, Merck discontinued its clinical trials of odanacatib due to stroke risk, however 
cathepsin K inhibition should not be ruled out as a target for treating reduced bone mass. 
Odanacatib has been shown to suppress inflammation and macrophage numbers in sites with 
increased inflammation such as periodontal and endodontic lesions [134, 135]. This result is an 
important finding for the potential treatment of inflammation-induced bone loss. The mechanism 
by which odanacatib alters macrophages is not clear. Given that macrophages are important cells 
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for the maintenance and turnover of bone, there is a need for further identification of the effects 
on macrophages by bone therapeutics. Off target effects of drugs may be due to macrophage 
responses versus traditional bone cell effects.   
 Antiresorptives are the most widely used therapeutic for the treatment of osteoporosis 
where they prevent further loss of bone in patients already exhibiting low bone mass. Due to the 
impact on reducing ongoing resorption, these agents provide increases in bone yet they do not  
stimulate bone formation. Teriparatide (hPTH 1-34) is the only anabolic osteoporosis therapeutic 
that has current US FDA approval. PTH-like analogs (ex. Abaloparatide) are currently under 
clinical investigation [136]. Parathyroid hormone (PTH), when pathologically elevated in the 
body or administered continuously, is catabolic in nature and acts as a signal to sequester 
calcium from the skeleton. However, if PTH is administered intermittently, an anabolic response 
leads to a net increase in bone [137, 138]. Teriparatide is currently only reserved for severe cases 
of osteoporosis due to its high cost, delivery method (injection), and black box warning 
attributed to the development of osteosarcomas in rats treated intermittently with PTH [139]. 
[139]. Any increase in risk of osteosarcoma in humans has not surfaced in the fourteen years it 
has been in clinical use [140, 141]. The exact mechanism of the anabolic response is still being 
investigated, and a better understanding of the effects of teriparatide will allow it to reach more 
patients with osteoporosis, to aid in the healing of fractures, and serve to treat patients with 
inflammatory diseases resulting in bone loss. Additionally, the delivery method is currently via 
subcutaneous injection and is administered systemically. Local delivery of teriparatide is under 
investigation for local bone regenerative application [142-144]. In rats, local intra-oral 
administration of PTH was as effective as subcutaneous injection in enhancing hard and soft 
tissue healing following tooth extraction [145]. Such application could have a positive impact in 
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conditions such as periodontal disease, bone defects or fractures where systemic administration 
has a demonstrated benefit [146, 147] but systemic application is unnecessary.   
 The role of macrophages has been outlined in the context of homeostatic bone turnover, 
disease and healing. Their role in mediating aspects of the PTH anabolic response is currently 
under investigation. Intermittent PTH treatment has been shown to be more effective when 
immune cells, such as macrophages, are present [78]. In a clinical trial investigating the effect of 
local teriparatide treatment of periodontal defects, disease sites displayed an anabolic response to 
teriparatide therapy, whereas non-diseased, non-inflamed sites showed no change in the same 
patient (although the study was not designed specifically to address this endpoint) [146].  
Additionally, the anabolic response is more robust in sites of injury such as tibial fracture, tooth 
extraction sockets, and endodontic lesions versus non-wounded bone [148, 149]. These findings 
led to the hypothesis that cells mediating the inflammatory process may be supportive of the 
anabolic response of intermittent PTH treatment. 
 The role of macrophages in mediating the anabolic response to intermittent PTH comes 
from mouse models of macrophage ablation. Mice treated with intermittent PTH display 
increased bone mass and an increase in F4/80-positive cells lining the periosteal and endosteal 
bone surfaces [78]. In the same study, macrophages were ablated using the MAFIA mouse model 
and mice were treated with intermittent PTH. The anabolic response was lost in the mice with 
depleted macrophages. Interestingly, when macrophages were depleted using clodronate-loaded 
liposomes, the anabolic response was amplified. This led to an investigation of the subsets of 
macrophages which were altered in the two macrophage ablation models. CD68-positive 
macrophages are mature macrophages which demonstrate phagocytic capacity. In the MAFIA 
mouse model, all macrophages were depleted including CD68-positive macrophages. 
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Conversely, in the clodronate-loaded liposome model, CD68-positive macrophages were 
amplified, an increase which may reflect a compensatory feedback loop [78]. These observations 
not only implicate a role for macrophages in the anabolic response to intermittent PTH therapy, 
but also demonstrate that particular macrophage subsets are necessary for the PTH response. 
Further investigation of the clodronate model showed an increase in whole bone marrow 
osteogenic gene expression including Wnt-3a, Wnt-10b and TGF-β1, all of which were further 
increased with PTH treatment [78]. The  source of the increase in gene expression is likely from 
a heterogeneous population of cells, but may be attributed to downstream effects of the increased 
CD-68+ cells and M2 macrophage upregulation. Studies investigating intermittent PTH 
treatment in non-lethally irradiated mice showed similar trends as the clodronate-loaded 
liposome model [150]. Non-lethal irradiation caused a decrease in marrow cells, however CD68+ 
cells were expanded. Mice treated with PTH following irradiation showed an increased anabolic 
response [150]. Due to the large amount of apoptosis that occurs following irradiation, 
efferocytosis machinery is likely altered to compensate for the influx and may lead to an 
upregulation of CD68+ phagocytic cells. This is consistent with the findings seen in the 
clodronate-loaded liposome model, and suggests that intermittent PTH therapy is enhanced in an 
environment in which apoptotic cell clearance is increased. As was seen in the clodronate model, 
TGF-β gene expression in the marrow was increased in the irradiated mice, a factor which may 
potentiate PTH effects [150]. Additionally, mechanical ablation of bone marrow in rats resulted 
in an increase in bone formation which was further increased with intermittent PTH therapy 
[151].  
 Further support of the hypothesis that the effects of intermittent PTH therapy are 
dependent on the macrophage actions comes from metabololipidomic profiling [92]. Intermittent 
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PTH increased proresolving mediators, including resolvin D1 and D2, in the bone marrow. 
Resolvins participate in the resolution phase of inflammation and mediate efferocytosis [152]. 
Human and mouse derived macrophages displayed increased engulfment of apoptotic osteoblasts 
when primed with resolvin D1 and D2 [92]. As macrophages do not have the PTH receptor, the 
mechanism by which PTH exerts its effects on macrophages is currently under investigation. 
PTH has been shown to have both pro- and anti-apoptotic effects on osteoblasts [153, 154]. In 
culture, early osteoblasts treated with PTH demonstrated decreased apoptosis, whereas mature 
osteoblasts treated with PTH displayed increased apoptosis. This led to the hypothesis that PTH 
promotes the apoptosis of less functional cells to promote reconstitution of the bone forming unit 
with younger, more functional osteoblasts. The increase in turnover of the osteoblast population 
may lead to the upregulation of alternatively activated M2-like macrophages and increased 
efferocytosis of apoptotic cells. The subsequent release of osteogenic factors leads to the 
recruitment of osteoblast precursors to facilitate the repopulation of the bone forming unit. 
The exact mechanism by which PTH may regulate macrophages is unknown, as 
macrophages do not express the PTH receptor. Osteoblasts carry the PTH receptor and respond 
to PTH treatment. Osteoblasts treated with PTH show increased expression of macrophage 
responsive factors such as M-CSF [155], IL-6 [156], sIL-6R [157], and chemokine (C-C motif) 
ligand 2 [158]. In the presence of PTH, osteoblasts may secrete factors which promote 
macrophage differentiation and recruitment, leading to increased availability of macrophages to 






Potential for targeted therapy that modulate macrophages to increase bone regeneration 
 Studies which have assessed the role of macrophages in the context of bone homeostasis 
have utilized models of macrophage ablation and characterized the aberrant effects. While these 
studies have shed light on the importance of this cell type on bone homeostasis, repair and 
anabolism, the ability to positively manipulate these cells to aid in bone regeneration is less 
appreciated. Clearly, targeting macrophages to assist in bone anabolism in cases of reduced bone 
mass or to aid in fracture repair shows promise in the field of bone biology.  Colony-stimulating 
factor-1 (CSF-1), mediates myeloid to monocyte, macrophage, dendritic cell and osteoclast 
differentiation [159-161]. CSF-1 has been investigated for its potential application in tissue 
repair including fracture healing [159, 162]. When CSF-1 was administered to rabbits during 
femoral osteotomy healing, mineralized bone was significantly increased compared to control 
groups [162]. Additional experiments employing the use of macrophage CSF-1 demonstrated 
that bone mass and formation are increased with CSF-1 treatment [163, 164] and in a mouse 
model of osteoporosis, M-CSF prevents ovariectomy-induced bone loss [165]. Interestingly, 
recent studies have demonstrated that CSF-1 treatment increases osteal macrophages but not 
osteoclasts [112, 113]. This suggests that the ability to positively manipulate osteal macrophage 
numbers is a viable therapeutic target. 
 OSM released from macrophages has been shown to be anabolic in nature [72-74, 114, 
166]. The therapeutic potential of this molecule has been explored, and could potentially serve to 
enhance osteoblastic differentiation and mineralization. An early experiment tested the potential 
of an adenoviral vector encoding murine OSM injected into knee joints to alter inflammation and 
stimulate bone formation [167]. OSM was shown to increase joint inflammation, but also 
displayed increased bone apposition at periosteal sites which correlated with increased 
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osteoblasts and decreased osteoclasts. Additionally, in lethally irradiated mice, OSM 
administration enhanced hematopoietic stem/progenitor cell recovery, suggesting OSM may 
serve to maintain the hematopoietic environment after injury. Like OSM, other factors that can 
be secreted by macrophages have been shown to be osteoinductive, including BMP-2 and could 
serve as potential therapies to enhance bone turnover. 
 The ability to directly target macrophages such that M1-like cells are decreased and M2-
like cells are increased may facilitate the positive effects of macrophages on bone. Treating 
inflammation-induced bone loss has centered on targeting the production of Th1 by T cells to 
reduce inflammation and decrease osteoclast activity [168]. These therapies undoubtedly would 
have effects on macrophages as well. For example, Abatacept is a receptor construct that targets 
CD80/CD86 and is used as an anti-inflammatory to treat rheumatoid arthritis [169], and 
Tocilizumab is a humanized monoclonal antibody to IL-6R and is also used to treat rheumatoid 
arthritis as well as juvenile idiopathic arthritis [170]. The exact effects of these therapeutics to 
alter macrophages in respect to bone turnover are not appreciated, but a better understanding of 
these processes can help identify optimal treatment regimens.  
In an interesting study of rheumatoid arthritis, injection of apoptotic thymocytes into the 
peritoneum reduced the presentation of rheumatoid arthritis in a streptococcal cell wall-induced 
rheumatoid arthritis model [171]. This was attributed to a decrease in TNF production by 
macrophages. This may also reflect an increase in resolution M2-like macrophages in response to 
the increased apoptotic cell insult. This further supports the idea that the process of efferocytosis 





Other macrophage-targeted therapies under investigation 
Altering macrophages to aid in the repair processes is not a new idea. In tissues other 
than bone, macrophages are potential targets for reducing symptoms of autoimmune diseases or 
enhancing tissue repair [172]. While many of these targeted therapies are still being investigated 
in animal models, clues from these studies in non-bone tissues may aid in the development of 
macrophage-targeted therapies to alter bone formation and repair. It is thought that an imbalance 
in M1/M2 macrophages that favors proinflammatory M1 cells is the basis for many diseases and 
issues with healing. Targeting macrophages to increase M2-like macrophages may serve to 
decrease any negative effects seen by increased M1-like cells. There are many drugs that are 
anti-inflammatory and could potentiate an M2 increase and a few will be reviewed here. 
A well accepted paradigm in macrophage biology is IL-4 mediates macrophage 
phenotypic switch toward the alternatively activated M2-like state. In a mouse model of 
myocardial infarction, M2-like cells predominate after cardiac injury. When M2 macrophages 
were depleted, mice showed significantly worse prognoses when myocardial infarction was 
induced [173]. Administration of IL-4 increased M2-like macrophages in mice and increased 
prognosis of myocardial infarcted mice. Early studies showed that IL-4 inhibits resorption [174], 
yet the therapeutic potential of IL-4 in fracture repair or osteoporosis therapy has not been 
thoroughly investigated and may serve as a positive regulator of repair and regeneration.  
Another example of an approach to target macrophage polarization is CD200. CD200 
interaction with its receptor increases alternatively activated macrophages [175]. Treatment of 
macrophages with human CD200-Fc up-regulated expression levels of M2-like markers and 
suppressed M1-like markers. These increases coincided with increased TGF-β expression in 
macrophages, and decreased proinflammatory macrophages. Interestingly, CD200 has been 
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shown to play a role in bone turnover and CD200 signaling may be a future therapeutic target to 
promote M2-like macrophages to aid in tissue repair. Although promising, macrophage plasticity 
targets must be explored more thoroughly in in animal models prior to pre-clinical settings to 
understand the complexity of the potential human response.  
 
Conclusions and Future Directions 
 The heterogeneity of macrophages, their varying functional roles, and plasticity make 
them difficult but exciting targets for therapeutic intervention. In the context of bone, certain 
macrophage subsets have been shown to mediate turnover and healing. However, it must be 
noted that most strategies to target macrophages in bone will likely have off-target effects on 
osteoclasts. This review has outlined the known roles of macrophages in bone, the potential 
mechanisms behind their pro-osteogenic effects and the possibility to target macrophages to aid 
in bone related disease treatment and fracture healing. It is promising that macrophage 
stimulating molecules in combination with current approved osteoporosis therapies could 
improve patient outcomes. Clearly, more in depth characterization of macrophages in bone must 












Figure 2.1. Tissue resident macrophages. (A) Macrophages are present in nearly all tissues in 
the body and perform different functional roles based on their location. (B) In the bone and bone 
marrow there consist several populations of macrophages. Osteoclasts are bone-resorbing cells 
which differentiate from monocyte precursors in the presence of M-CSF and RANKL. Erythroid 
island macrophages (EIM) are found interacting with and supporting erythroblasts during 
erythropoiesis. These macrophages are distinct from HSC niche macrophages which are found 
adjacent to blood vessels and support HSC self-renewal and cycling. Osteal macrophages are 
found adjacent to bone forming cells (osteoblasts), dormant bone-lining cells, and osteoclasts. 
The functional role of osteal macrophages is proposed to support bone formation through 
























Figure 2.2. F4/80 positive cells are located throughout the marrow and intimately 
associated with bone surfaces. Tibiae from 22-week old C57BL/6 mice were paraffin 
embedded, sectioned and immunohistochemical stained (brown) for F4/80 and counterstained 
with hematoxylin (blue) as previously described [78]. Macrophages are located adjacent to bone 
surfaces (black arrowheads) and throughout the marrow space. F4/80+ cells are also associated 














Figure 2.3. Internalization of apoptotic bone marrow stromal cells by macrophages. Bone 
marrow macrophages were stained for F4/80-FITC and apoptotic bone marrow stromal cells 
(BMSCs) stained with Cell Tracker Deep Red, co-cultured for 1hr and analyzed via flow 
cytometry. Representative fluorescence-activated cell sorting (FACs) dot plots (left) indicate 
macrophages alone (R1), apBMSCs alone (R2), or macrophages with internalized apoptotic 
BMSCs (R3). Representative photo from Image Stream which captures single cell images 
showing either single cells or engulfment (right). These images depict efferocytosis at two 
stages, recognition and internalization, and demonstrate that bone marrow macrophages in 














Table 2.1. Bone macrophage markers and roles. 



























Support and regulate HSC 
niche self-renewal and 
cycling 
[68, 77, 177, 
178] 





Support bone homeostasis 
Support fracture healing 
[3, 113] 
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Apoptosis occurs at an extraordinary rate in the human body and the effective clearance 
of dead cells (efferocytosis) is necessary to maintain homeostasis and promote healing, yet the 
contribution and impact of this process in bone is unclear. Bone formation requires that bone 
marrow stromal cells (BMSCs) differentiate into osteoblasts which direct matrix formation and 
either become osteocytes, bone lining cells, or undergo apoptosis. A series of experiments were 
performed to identify the regulators and consequences of macrophage efferocytosis of apoptotic 
BMSCs (apBMSCs). Bone marrow derived macrophages treated with the anti-inflammatory 
cytokine interleukin-10 (IL-10) exhibited increased efferocytosis of apBMSCs compared to 
vehicle treated macrophages. Additionally, IL-10 increased anti-inflammatory M2-like 
macrophages (CD206+), and further enhanced efferocytosis within the CD206+ population.  
Stattic, an inhibitor of STAT3 phosphorylation, reduced the IL-10-mediated shift in M2 
macrophage polarization and diminished IL-10-directed efferocytosis of apBMSCs by 
macrophages implicating the STAT3 signaling pathway. Cell culture supernatants and RNA 
from macrophages co-cultured with apoptotic bone cells showed increased secretion of 
monocyte chemotactic protein 1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) and 
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transforming growth factor beta 1 (TGF-β1) and increased ccl2 gene expression. In conclusion, 
IL-10 increases M2 macrophage polarization and enhances macrophage-mediated engulfment of 
apBMSCs in a STAT3 phosphorylation-dependent manner. After engulfment of apoptotic bone 
cells, macrophages secrete TGF-β1 and MCP-1/CCL2 both factors that fuel the remodeling 
process.  A better understanding of the role of macrophage efferocytosis as it relates to normal 
and abnormal bone turnover will provide vital information for future therapeutic approaches to 
treat bone related diseases. 
 
Introduction 
The critical process of bone formation depends on the lifespan and activity of osteoblasts 
lining the bone surface. Three fates have been described for osteoblasts: they either become 
osteocytes embedded in mineralized matrix, bone-lining cells which form layers over bone 
surfaces and at remodeling sites, or they undergo programmed cell death (apoptosis). Of the 
osteoblasts initially at remodeling sites, 30-50% become osteocytes and bone-lining cells, which 
leaves a large percentage of cells thought to undergo apoptosis [1]. The course of events after 
osteoblast apoptosis has been under appreciated.  This is in part due to the inability of assays to 
accurately detect and quantify apoptotic osteoblasts readily undergoing apoptosis. In normal 
physiology, cell death is followed by rapid and efficient removal of apoptotic cells by phagocytic 
cells, predominantly macrophages. This process of apoptotic cell recognition and clearance is 
termed efferocytosis [2].   
Macrophages are immune cells known for their role in infection and inflammation. A 
focus on their role in bone has only recently emerged [3]. Macrophages are prominent players in 
bone homeostasis and are highly implicated in fracture healing [4-6].  They are often found at 
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sites of remodeling, and are intimately associated with bone forming osteoblastic cells. 
Additionally, macrophage numbers increase significantly in fracture sites, and bone repair is 
severely diminished after tibial injury in macrophage-ablated mouse models [5]. Apoptotic cells 
increase in sites of injury, and a crucial component of the healing process is the effective 
clearance of these cells by phagocytes, including macrophages. The recognition and subsequent 
efferocytosis of dead and dying cells leads to the secretion of anti-inflammatory cytokines such 
as TGF-β and IL-10 [7, 8], as well as osteoinductive factors including osteopontin, and BMP-2 
[9-11]. The process of efferocytosis has been extensively studied in other tissues. Recently, 
macrophages were found to efferocytose apoptotic osteoblasts [12] yet the impact of 
efferocytosis in bone has not been clearly defined.  
Macrophages have been shown to polarize into two populations: classically activated M1 
macrophages and alternatively activated M2 macrophages. M2 macrophages are present during 
the resolution phase of inflammation and are responsible for anti-inflammatory cytokine 
production and enhanced efferocytosis [13, 14]. In the presence of the anti-inflammatory 
cytokines IL-4 and IL-10, macrophages polarize to M2-like macrophages [15], and increase 
apoptotic lymphocyte and apoptotic neutrophil clearance [16, 17]. IL-10 is an important bone 
cytokine which inhibits osteoclastogenesis [18] and exhibits a protective role in periodontal 
disease [19]. Furthermore, IL-10 deficient mice exhibit low bone mass phenotypes with reduced 
bone formation compared to wild-type controls [18, 20]. To our knowledge, the role of IL-10-
induced efferocytosis in bone has not been investigated.  
Additonally, it is unclear which factors regulate the clearance of apoptotic bone cells by 
bone resident macrophages and how macrophages respond to the englulfment of an apoptotic 
bone cell. The apoptotic cell identity can impact the response elicited by the phagocyte and the 
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response of a bone marrow macrophage to an apoptotic bone cell is of interest to the present 
work. This study aimed to determine factors and signaling which affect macrophage 
efferocytosis of apoptotic osteoblastic cells and changes in macrophage gene expression in 




All animals were maintained in accordance with institutional animal care and use guidelines, and 
experimental protocols were approved by the Institutional Animal Care and Use Committee of 
the University of Michigan. C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) mice were 
used for in vitro experiments unless otherwise indicated. Human CD68-GFP reporter mice 
(hCD68-GFP) mice were generously provided by Dr. Ajay Chawla (University of California San 
Francisco). hCD68-GFP mice were generated by cloning a cDNA fragment encoding EGFP 
(from pEGFP-N1 vector, Invitrogen) into the 1265 vector containing human CD68 promoter 
(−2.9 kb). DNA was then excised from the vector and injected into mouse oocytes by pro-
nuclear injection [21].   
 
Cell Culture 
Primary bone marrow cells were collected from 4-8 week old C57BL/6J or hCD68-GFP mice. 
Bone marrow-derived macrophages (BMMs) were differentiated in vitro from bone marrow 
flush in α-MEM medium (10% FBS, Pen/Strep, glutamine) with murine M-CSF (30ng/mL 
eBioscience) for 6 days. At day 7, macrophages were plated at 2.5 x 105 cells/well in 12-well 
plates (for efferocytosis assays) or 1.5 x 106 cells/well in 6-well plates (for protein/RNA). Bone 
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marrow stromal cells (BMSCs) were derived from bone marrow flush and cultured in α-MEM 
medium (20% FBS, Pen/Strep, glutamine) containing 10nM dexamethasone (Sigma) and used at 
passage 1-2. Bone marrow neutrophils were isolated as previously described [22].  Briefly, bone 
marrow was flushed from 8-12 week old C57BL/6J mice with RPMI supplemented with 10% 
FBS and 2 mM EDTA, red blood cells lysed using 0.2% NaCl, and neutrophils separated by 
density gradient centrifugation (Histopaque 1119 and Histopaque 1077).  Neutrophils were 
harvested at the interface of the Histopaque 1119 and Histopaque 1077 layers and confirmed 
using FACs anaylsis for CD11b+Ly6G+ cells. 
 
Macrophage treatment 
All recombinant murine proteins were obtained from R&D Systems. BMMs were treated at day 
8 with rmIL-10 (0.1-100ng/mL), rmCCL2/MCP-1 (10ng/mL), rmMFG-E8 (10ng/mL), sIL-6R 
(100ng/mL), or vehicle (0.5% BSA in 1X PBS) for 4-24 hours in low serum containing media 
(0.5% FBS). In a set of experiments BMMs were pre-treated with an inhibitor of pSTAT3 
(Stattic, 6.25µM, CalBiochem) or DMSO (vehicle) 2 hours prior to rmIL-10 treatment.  
 
Efferocytosis Assay 
BMSCs were stained with CellTracker Deep Red (APC+, Invitrogen) and exposed to UV light 
for 30 minutes to induce apoptosis. Apoptotic BMSCs (apBMSCs) were recovered for 2 hours at 
37ºC, enumerated via trypan blue exclusion (confirming cell death), and added to BMM cultures 
at a 1:1 ratio for 0.5-6 hours. BMMs co-cultured with apBMSCs were harvested and stained with 
F4/80-FITC (Abd Serotec, CI:A3-1), fixed with 1% formalin and efferocytosis was assessed via 
flow cytometric (FACs) analyses (BD FACSAriaTM III) for double labeled cells (FITC+APC+) 
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reflecting engulfment. Macrophages cultured alone were harvested and stained with the 
following macrophage-specific antibodies: F4/80 FITC (CI:A3-1, BIORAD), CD86 PE (GL-1, 
Biolegend,) and CD206 PE (C068C2, Biolegend). Cells were fixed, permeabilized with 
Permeabilization Buffer (Biolegend), incubated with CD68 PE (Y1/82A, Biolegend) and 
assessed via FACs analyses.  
 
Confocal microscopy 
BMMs from hCD68-GFP mice were plated in 1.5-mm coverglass chambers (8 x 104 cells/well), 
treated for 24 hours with vehicle or rmIL-10 (10ng/mL) and apBMSCs (stained with CellTracker 
DeepRed) were added at a 1:1 ratio to BMMs for 1 to 24 hours and fixed with ice-cold methanol 
for 20 mins. Cells were then washed with PBS and covered with ProLong® Gold antifade 
reagent with DAPI (Life Technologies). Confocal microscopy images were analyzed using the 
Leica inverted SP5X confocal microscope system with two-photon film and Leica software 
(Leica Microsystems). 
 
Mouse Inflammation Antibody Array 
BMMs were plated into 6-well dishes (1.5 × 106 cells/well), then co-cultured with or without 
apBMSCs at a 1:1 ratio in α-MEM (0.25% FBS). Supernatants were collected after 18 hours and 
proteins were analyzed using the mouse inflammation antibody array C1 (catalog no. AAM-INF-







Supernatants were collected from BMMs alone, BMMs/apBMSCs or BMMs/apNeutrophils after 
18 hours of co-culture. TGF-β1 protein levels in culture supernatants were measured with the 
Quantikine mouse TGF-β1 ELISA (R&D systems) per manufacturer’s instructions. Briefly, acid-
activated supernatant samples, standards, and controls were added to anti-mouse TGF-β1 
antibody pre-coated microplates and incubated at room temperature for 2 hours. Wells were 
washed and incubated with TGF-β1 conjugate for 2 hours, washed and substrate solution added 
for 30 minutes.  Stop solution was added and A450 values (corrected with A570) were measured 
using an EZ Read 400 microplate reader (Biochrom). 
 
QRT-PCR 
Total RNA was isolated from BMMs alone, apBMSCs alone and BMM/apBMSC co-culture 
after 18 hours using the Qiagen RNeasy Mini Kit.  Reverse transcription PCR was conducted, 
and the cDNA products were amplified and detected using TaqMan Universal PCR master mix 
(Applied Biosystems) and TaqMan probes, including mouse Ccl2 (Mm00441242_m1) and 
mouse Actb (Mm02619580_g1) as an endogenous control. Realtime PCR was analyzed on ABI 
PRISM 7700 (AppliedBiosystems). 
 
Statistical Analyses 
Statistical analyses were performed by unpaired Student's t test to compare two groups or 
ANOVA to compare three or more groups with a significance of p < 0.05. Data are presented as 





IL-10 Enhances Bone Marrow Derived Macrophage Engulfment of Apoptotic Bone Marrow 
Stromal Cells 
To investigate the impact of IL-10 on macrophage-mediated efferocytosis of apoptotic 
bone cells, bone marrow macrophages (BMMs) were treated with IL-10 and efferocytosis of 
apoptotic bone marrow stromal cells (apBMSCs) was determined. BMMs (F4/80-FITC+) were 
co-cultured with apBMSCs (DeepRed-APC+) and double positive (FITC+APC+) cells were 
quantified using flow cytometric cell sorting, reflecting engulfment (Figure 3.1A, left panel).  
Engulfment was confirmed by ImageStream analysis which images individual cells in the flow 
stream to confirm the presence of fluorescent markers. Double-positive cells were confirmed to 
to be FITC+-macrophages associated with APC+-apBMSCs (Figure 3.1A). To assess the effect 
of various cytokines on efferocytosis, BMMs were treated with IL-10, CCL2, MFG-E8 and sIL-
6R for 24 hours and efferocytosis of apBMSCs measured after 1 hour of co-culture. These 
cytokines were chosen based on their ability to regulate efferocytosis in non-skeletal tissues (IL-
10 and MFG-E8) or important bone formation regulators (CCL2 and sIL-6R). IL-10 enhanced 
engulfment of apBMSCs by 22% and in a dose-dependent manner (Figure 3.1B and C), 
whereas MCP1, MFG-E8 and sIL-6R did not demonstrate significant changes in efferocytosis at 
that time point.  To determine the optimum IL-10 treatment length, BMMs were treated for 4-48 
hours with IL-10.  BMMs treated for 24 hours with IL-10 displayed increased efferocytosis 
compared to shorter treatment times (Figure 3.1D).  Macrophages treated with IL-10 for 24 
hours showed enhanced efferocytosis when co-cultured for shorter durations (0.5-2 hours) 
compared to longer co-cultures (6 hours), suggesting IL-10 increased the rate of efferocytosis 
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(Figure 3.1E). IL-10 treatment of BMMs enhanced engulfment of apBMSCs in a time and dose-
dependent manner. 
 
IL-10 Polarizes Bone Marrow Derived Macrophages to M2-like Phenotype with Enhanced 
Efferocytic Capacity 
Macrophages are described as classically (M1) or alternatively (M2) activated. M2 
polarized macrophages are resolving cells with higher efferocytic capacity than M1 macrophages 
[13]. To determine the impact of IL-10 treatment on BMM phenotypes, equal numbers of BMMs 
were treated with IL-10 for 24 hours and assessed for M1 (F4/80+CD86+) and M2 
(F4/80+CD206+) polarization. IL-10 did not affect cell number or viability (Figure 3.2A), mature 
(CD68+) or M1 macrophages (Figure 3.2B).  Treatment with IL-10 significantly increased M2 
polarization of BMMs (Figure 3.2C). This effect of IL-10 is consistent with previous reports 
[23, 24], however, the impact of IL-10 within the M2 population is unclear.  To investigate the 
role of IL-10 on altering efferocytosis within the CD206+ population, efferocytosis of apBMSCs 
by CD206+ cells was measured.  IL-10 increased the percentage of CD206+ cells that 
efferocytosed apBMSCs (Figure 3.2D), suggesting that IL-10 not only polarized BMMs to M2 
macrophages, but also specifically enhanced their efferocytic ability.   
 
IL-10 Increases Efferocytosis in a STAT3 Activation Dependent Manner  
IL-10 signals through the JAK/STAT pathway and inhibition of JAK/STAT signaling has 
been shown to decrease efferocytosis [25]. To measure the effect of JAK/STAT pathway 
inhibition on IL-10 induced efferocytosis, BMMs were pre-treated with the phospho-STAT3 
(pSTAT3) inhibitor Stattic prior to IL-10 treatment and efferocytosis measurement.  BMMs were 
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isolated from mice which express GFP under the human CD68 promoter to visualize CD68+ 
(mature phagocytic) cells (Figure 3.3A).  Macrophages harvested from the hCD68-GFP mice 
displayed increased efferocytosis of apBMSCs following IL-10 treatment as measured by FACs 
analysis and confocal microscopy (Figure 3.3B and C). BMMs pre-treated for 2 hours with 
Stattic and subsequently treated with IL-10 had reduced efferocytosis of apBMSCs compared to 
DMSO control treated macrophages (Figure 3.3D).  Macrophages pre-treated with Stattic 
followed by vehicle treatment also displayed decreased efferocytosis compared to controls 
suggesting some baseline efferocytosis in vehicle treated macrophages requires signaling through 
the JAK/STAT pathway, likely by other cytokine signaling. To investigate the role of 
JAK/STAT signaling in IL-10 induced M2 polarization, BMMs were treated with Stattic for 2 
hours followed by IL-10 treatment and assessed for CD206+ (M2 polarization).  In vehicle 
treated BMMs, Stattic did not alter the M2 population; however, Stattic treatment prior to IL-10 
treatment significantly reduced the IL-10 mediated M2 shift in macrophage polarization (Figure 
3.3E) suggesting that IL-10 shifts macrophage polarization and enhances efferocytosis of 
apBMSCs via signaling through JAK/STAT pathway. 
 
Macrophages Secrete MCP-1/CCL2 and TGF-β1 in Response to Apoptotic Bone Marrow 
Stromal Cells 
Macrophages release factors when engulfing apoptotic cells that signal to surrounding 
cells [8, 26, 27]. To determine the response of macrophages to apBMSCs, BMMs were cultured 
alone or with apBMSCs for 18 hours and supernatants harvested for analysis of secreted 
proteins.  Supernatants harvested from co-culture of BMMs with apBMSCs showed significantly 
increased secreted CCL2 levels compared to macrophages cultured alone (Figure 3.4A).  RNA 
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harvested from macrophages co-cultured with apBMSCs also showed increased ccl2 gene 
expression (Figure 3.4B) compared to BMMs alone or BMMs co-cultured with apoptotic 
neutrophils.  In other tissues, TGF-β1 is an important anti-inflammatory cytokine released from 
macrophages after efferocytosis [8].  Supernatants from macrophages cultured with apBMSCs 
versus macrophages alone or versus macrophages cultured with apoptotic neutrophils displayed 
increased total secreted TGF-β1 levels (Figure 3.4C).  Hence, in response to engulfment of 
apoptotic bone cells, bone marrow macrophages secrete the anti-inflammatory cytokine TGF-β1 
and chemokine CCL2, which are both important factors related to bone homeostasis.  
 
Discussion 
Patients exhibiting increased inflammation associated with diseases such as rheumatoid 
arthritis and inflammatory bowel disease are often at a higher risk of generalized osteoporosis 
and increased fracture risk [28-30]. Chronic inflammation is associated with systemic 
overproduction of pro-inflammatory mediators, which are thought to play a role in decreasing 
bone formation [31].  Periodontal disease activates macrophages and triggers systemic 
inflammation of the vasculature and atherosclerotic signs [32].  Macrophages are immune cells 
which mediate pro-inflammatory or anti-inflammatory conditions yet little is known about their 
role in the basic cell biology of bone.  
Macrophages have recently become of interest in the bone field due to their intimate 
association with the bone forming unit and contributions to osteoblast function [4-6]. It is 
hypothesized that the anti-inflammatory function of macrophages and the clearance of apoptotic 
cells may contribute to bone turnover and regeneration [12].  In humans, billions of cells die 
daily which is unappreciated by current methods used to detect apoptotic cells from in vivo tissue 
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samples.  This is due to the rapid and effective clearance of apoptotic cells, termed efferocytosis 
[2].  Macrophages are vital mediators of cellular turnover, maintenance of extracellular matrix 
homeostasis and modulation and resolution of inflammation [33].  Understanding their 
mechanisms of action as they relate to bone remodeling provides a basis for the prevention and 
treatment of chronic inflammatory conditions. 
Anti-inflammatory cytokines such as IL-4 and IL-10 released by immune cells have been 
shown to increase human peripheral blood macrophage engulfment of non-bone associated 
apoptotic cells [16, 17]. IL-10 contributes to bone turnover by regulating osteoclastogenesis and 
IL-10 deficient mice display osteopenia [20, 34], but the role of IL-10-associated efferocytosis 
by bone marrow macrophages is largely unknown. To study mechanisms of efferocytosis in bone 
marrow derived macrophages, a series of in vitro experiments were performed to determine how 
bone macrophages respond to apoptotic bone marrow stromal cells and what factors may 
influence the rate of engulfment. IL-10 treated macrophages displayed enhanced clearance of 
apoptotic bone marrow stromal cells.  The effect of IL-10 on bone marrow macrophages was in 
part due to polarization of macrophages toward the pro-resolving M2 phenotype. While there 
was a significant increase in M2 macrophages, the increase was not the only contributing factor 
to an increase in efferocytosis.  The CD206+ M2 macrophages displayed increased efferocytosis 
of apoptotic bone cells after treatment with IL-10 compared to vehicle treated macrophages.  
This suggests that not only does IL-10 polarize macrophages to M2, but it also enhances the M2 
macrophage efferocytic capacity.   
 The effect of IL-10 on efferocytosis of apoptotic lymphocytes and neutrophils has been 
measured, and downstream signaling of IL-10 has been identified [16, 17]. IL-10 signals through 
the JAK/STAT pathway, in which STAT3 is phosphorylated, dimerizes and translocates to the 
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nucleus to regulate transcription of various genes [35-37].  To validate the downstream events of 
IL-10 signaling, macrophages were treated with an inhibitor of STAT3 phosphorylation (Stattic) 
prior to IL-10 treatment.  Efferocytosis of apoptotic bone cells was decreased with Stattic 
treatment, demonstrating that the IL-10 effect occurs in a pSTAT3-dependent manner.  Previous 
studies have also indicated that inhibition of STAT3 phosphorlyation decreases MFG-E8 
mediated phagocytosis of apoptotic mimicry beads [25].   
Following IL-10 activation of macrophages and efferocytosis of apoptotic bone cells, 
proteins released by macrophages signal to surrounding cells.  How macrophages respond to 
apoptotic bone cells may indicate what effects efferocytosis have on bone modeling and 
remodeling. The identity of the apoptotic cell, bone marrow stromal cells in this case, contributes 
to the profile of genes upregulated in macrophages partaking in efferocytosis. In the present 
study, bone marrow derived macrophages increased secretion of monocyte chemoattractant 
protein-1/CC chemokine ligand 2 (MCP-1/CCL2) after co-culture with apoptotic bone cells. 
CCL2 is associated with monocyte/osteoclast precursor recruitment and enhances 
osteoclastogenesis [38]. These data suggest that CCL2 secreted from macrophages engulfing 
apoptotic bone cells could aid in the recruitment of monocytes to enhance bone turnover by 
increasing osteoclasts and bone macrophages. 
  TGF-β1 was also found to be increased after efferocytosis of apBMSCs. Previous studies 
using human peripheral blood macrophages showed increased TGF-β1 levels following 
efferocytosis of apoptotic human derived neutrophils [8]. The release of TGF-β1 following 
apoptotic cell engulfment is often credited with an anti-inflammatory function.  Interestingly, in 
the context of bone, TGF-β1 enhances the recruitment of mesenchymal stem cells which are 
precursors to osteoblastic cells [39, 40].  The secretion of TGF-β1 in response to apoptotic bone 
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cells may contribute to repopulating the bone forming units.  Other osteogenic factors such as 
BMP-2 and osteopontin have been shown to be released from M2 macrophages, but it is unclear 
how the protein levels change during the process of efferocytosis [10, 11].   
 Macrophages are crucial regulators of bone turnover in steady state bone remodeling and 
wound healing [4, 5]. A better understanding of the role of these macrophages is important in 
developing ways to utilize macrophages in therapeutic interventions for osteoporosis, fracture 
healing, periodontal wound healing, and osteonecrosis. These data demonstrate one mechanism 
by which macrophages efferocytose apoptotic bone cells and their subsequent release of factors 
important in bone remodeling (Figure 3.5).  Future work to determine the association of 
efferocytosis and bone turnover is important to better understand the mechanisms by which 





















Figure 3.1. IL-10 treatment enhanced efferocytosis of apoptotic bone marrow stromal cells 
(apBMSCs) by bone marrow derived macrophages (BMMs).  (A) BMMs were stained for 
F4/80-FITC and apBMSCs stained with Cell Tracker Deep Red, co-cultured for 1hr and 
analyzed via flow cytometry. Representative fluorescence-activated cell sorting (FACs) dot plots 
(left) indicate macrophages alone (green gate), apBMSCs alone (red gate), or macrophages with 
internalized apBMSCs (yellow gate). Representative photo from Image Stream which captures 
single cell images showing either single cells or engulfment. (B) BMMs treated for 24hrs with 
vehicle, rmIL-10 (10ng/mL), rmMCP-1 (10ng/mL), rmMFG-E8 (500ng/mL) or sIL-6R 
(500ng/mL) and co-cultured with apBMSCs for 1hr. Efferocytosis was measured as percentage 
of F4/80+ cells which were apBMSC+. IL-10 treatment increased efferocytosis compared to 
vehicle control. (C) BMMs were treated for 24hrs with rmIL-10 (0.1-100ng/mL) and co-cultured 
with apoptotic BMSCs for 1hr. IL-10 (1.0-100ng/mL) increased efferocytosis of apBMSCs. (D) 
BMMs were treated with IL-10 (10ng/mL) for 4-48hrs and co-cultured with apBMSCs for 1hr.  
Treatment of macrophages with rmIL-10 for 24-48hrs induced a larger increase in efferocytosis 
relative to shorter treatment times. (E) BMMs treated for 24hrs with IL-10 or vehicle control and 
co-cultured with apoptotic BMSCs for 0.5-12hrs. IL-10 increased engulfment of apBMSCs after 













Figure 3.2. IL-10 polarizes BMMs to alternatively activated (M2) phenotype. (A) BMMs 
were treated with rmIL-10 (10ng/mL) for 24hrs and enumerated.  IL-10 did not change cell 
number compared to vehicle controls or viability, (B) BMMs treated for 24hrs with rmIL-10 
were analyzed via FACs for phagocytic cells (CD68) and M1 macrophage phenotype (CD86). 
No significant changes were observed in these cell populations with IL-10 treatment.  (C) BMMs 
treated with IL-10 were analyzed via FACs analysis for alternatively activated M2 macrophages 
(CD206). IL-10 treatment significantly increased the CD206hi population per CD206+. (D) 
BMMs treated with IL-10 showed enhanced efferocytosis of apBMSCs within the CD206+ 
population after 1hr co-culture as evidences by increased CD206+apBMSCs+ double positive 






Figure 3.3. Stat3 inhibition diminished IL-10 effect. (A) BM cells were harvested from 4-8wk 
old hCD68-GFP mice, enriched to macrophages with M-CSF then analyzed for GFP retention. 
FACs analysis showed that the majority of CD68-PE+ cells were also GFP+, indicating GFP was 
retained during in vitro culture. (B) hCD68-GFP BMMs were treated with IL-10 for 24 hours 
and efferocytosis of apBMSCs harvested from C57BL/6J analyzed via FACs analysis.  IL-10 
significantly increased the percentage of GFP+ cells which were also positive for apBMSCs 
(Deep Red).  (C) hCD68-GFP BMMs were treated with IL-10 for 24 hours and efferocytosis of 
apBMSCs analyzed via confocal microscopy. (D) hCD68-GFP BMMs were treated with Stat3 
inhibitor (Stattic, 6.25µM) or DMSO for 2 hours followed by IL-10 or vehicle treatment for 24 
hours. Efferocytosis of apBMSCs was analyzed via FACs analysis for double positive 
GFP/apBMSCs cells (representative dot plots on left). Stat3 inhibitor decreased efferocytosis of 
apBMSCs in vehicle and IL-10 treated BMMs. (E) Alternatively activated macrophage 
phenotype (CD206-PE) was increased in IL-10 treated BMMs and the effect was diminished 
with Stattic pre-treatment. n = 6/group, data is mean ± SEM. *p <0.05, ** p <0.01, ***p <0.001 




































Figure 3.4. Macrophage efferocytosis induces CCL2 and TGF-β1 secretion. (A) 
Supernatants were harvested from BMMs, apBMSCs or co-culture of BMMs with apBMSCs for 
18hrs and analyzed for secreted proteins using a murine inflammatory cytokine array.  Co-
culture of BMMs with apBMSCs showed significantly increased secreted CCL2 compared to 
BMMs or apBMSCs cultured alone (arbitrary units, a.u.). (B) RNA was isolated from BMMs 
alone or co-cultured with apBMSCs or apoptotic neutrophils and QRT-PCR performed for ccl2 
mRNA.  Ccl2 gene expression was increased in co-culture of BMMs with apBMSCs compared 
to BMMs alone. (C)  ELISA for total TGF-β1 levels in the supernatants showed increased 
secreted TGF-β1 after 18hrs of co-culture of BMMs with apBMSCs compared to BMMs, n=6/gp 






Figure 3.5. Model. IL-10 promotes M2 macrophage polarization and enhances clearance of 
apoptotic bone marrow stromal cells in a STAT3-phosphorylation dependent manner. Clearance 
of apoptotic cells results in release of anti-inflammatory and osteoinductive factors (TGF-β1 and 
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MFG-E8 DEFICIENCY: A MODEL OF INFLAMM-AGING ASSOCIATED BONE 
LOSS RESCUED BY TERIPARATIDE 
 
Abstract 
Multiple processes become less efficient with age leading to chronic increases in pro-
inflammatory cytokines, termed inflamm-aging [1]. This process has been associated with 
osteoporotic- and autoimmune-associated bone loss. Crucial components of anti-inflammatory 
pathways are associated with age-related bone loss. Milk fat globule-EGF 8 (MFG-E8) is a 
glycoprotein that is pro-resolving, regulates apoptotic cell clearance and has recently been linked 
to autoimmune disease and skeletal homeostasis. The role of MFG-E8 in the skeleton was 
determined with age in mice deficient in MFG-E8 (KO). In vivo, trabecular bone was similar in 
MFG-E8 KO and wildtype (WT) mice at 6 and 16wks, whereas 22wk MFG-E8 KO mice 
displayed significantly reduced trabecular bone. Osteoclast number per bone surface was 
increased in 22wk KO vs. WT and osteoclasts treated with recombinant murine MFG-E8 were 
decreased in number and size. Adult MFG-E8 KO spleen weight/body weight was increased 
compared to WT and FACs analysis showed significantly increased myeloid derived suppressor 
cells (CD11bhiGR-1+) and neutrophils (CD11bhiLy6G+) in MFG-E8KO bone marrow, suggesting 
an increase in inflammation. Interestingly, iPTH-treated MFG-E8 KO mice showed a robust 
anabolic response in trabecular BV/TV, exceeding the response in iPTH-treated WT mice. The 
strong anabolic response in MFG-E8 deficient mice demonstrates that iPTH therapy may be 
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highly effective in models of age-related bone loss and/or inflammatory states. These data give 
insight into the role of MFG-E8 in aging, provide a new model of age-associated bone loss, and 




 Milk fat globule epidermal growth factor 8 (MFG-E8) is a secreted glycoprotein which 
was first identified in the mammary gland and then studied extensively in many other tissues [2-
5]. One of the most prominent functions of MFG-E8 is to act as a bridge between apoptotic cells 
and phagocytic cells thus coordinating the engulfment of apoptotic cells, a process termed 
efferocytosis [6-9]. MFG-E8 has also been linked to other functions in the body including 
collagen clearance by lung alveolar macrophages [3], angiogenesis in cutaneous wound healing 
[10], phagocytosis in the retina [5], and polarization of tumor associated macrophages [11]. 
MFG-E8 is also an important regulator of the inflammatory response, and mice deficient in 
MFG-E8 have inflammatory phenotypes including intestinal colitis and systemic lupus 
erythematous (SLE)-like symptoms [7, 12, 13]. In humans, a genetic polymorphism of MFG-E8 
correlated significantly to human SLE [14].  
The role of MFG-E8 has recently emerged in bone where it was found to be a positive 
regulator of bone turnover [15] and a protective factor against rheumatoid arthritis [16]. MFG-E8 
deficient mice have reduced bone mass as well as accelerated bone loss in a ligature-induced 
periodontitis model [17], yet the exact functional role of MFG-E8 in bone turnover is still 
unclear. MFG-E8 expression leads to an anti-inflammatory response. Chronic inflammatory 
states increase with age and support osteoclast differentiation and activity. The aging skeleton 
presents with reduced osteoblast activity and increased osteoclast activity leading to a net 
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reduction in bone [18, 19]. Additionally, with age, the body has reduced efficiency of a variety of 
processes and associated chronic elevation of pro-inflammatory cytokines. Age associated 
inflammation has been termed inflamm-aging [1]. The contributions of many inflammatory 
cytokines to age-associated osteoporosis have been studied and well characterized, however the 
role of resolving or anti-inflammatory cytokines are less well characterized. Due to the resolving 
nature of MFG-E8 it is hypothesized that it plays a role in age-associated inflammation and bone 
loss.  
 Teriparatide (human parathyroid hormone, hPTH 1-34) is an FDA approved injectable 
anabolic therapeutic used in cases of severe osteoporosis. Its mechanism has been widely studied 
and intermittent daily treatment (iPTH) results in an increase in overall bone turnover and a 
resultant increase in bone formation and bone mass. PTH effects on bone marrow cell 
populations have also been investigated and have been shown to alter marrow neutrophils and 
macrophages [20, 21]. The therapeutic potential of PTH in rescuing inflammation-induced bone 
loss is less understood.  Additionally, therapeutic interventions to rescue MFG-E8 associated 
bone loss have not been investigated. The purpose of the present study was to assess the role of 
MFG-E8 in the aging skeleton and investigate an anabolic therapeutic intervention in MFG-E8 
deficient mice.  
  
Materials and Methods 
Animals 
All mice were maintained in accordance with institutional animal care and use guidelines, and 
experimental protocols were approved by the Institutional Animal Care and Use Committee of 
the University of Michigan. MFG-E8 deficient (KO) mice were originally created using a gene 
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trap vector and backcrossed into C57BL/6 background (WT controls) [2, 3]. Female mice were 
used for in vitro or in vivo experiments at ages 6, 16 or 22 weeks. To test the anabolic effect of 
intermittent parathyroid hormone (iPTH), 16 week old KO and WT mice were treated daily with 
recombinant human PTH (1-34) (Bachem, Torrance, CA) (50μg/kg, SC) or vehicle (0.9% saline, 
SC) for 6 weeks.  MFG-E8KO mice were crossed with Mertk KO mice (Jackson Laboraties) to 
create double MFG-E8/Mertk KO mice (dKO). Skeletal phenotypes were assessed at 6, 16, and 
22 weeks and were treated in the same manner as KO mice with iPTH.  
 
Complete Blood Counts (CBC) 
Blood was harvested at time of euthanasia via intracardiac puncture from mice at ages 6, 16, and 




Mice underwent food and water restriction for 6 hours prior to serum collection. Blood was 
harvested as above, and placed in non-EDTA containing microcentrifuge tubes, allowed to 
coagulate for at least one hour at room temperature, spun down at 8000 rpm for 10 minutes, and 
liquid serum collected into new microcentrifuge tubes. Samples were stored at -20°C until use. 
Enzyme immunoassays were used to measure the serum concentrations of tartrate-resistant acid 
phosphatase form 5b (TRAcP 5b), propeptide of type I procollagen (P1NP) and C-telopeptide of 
type I collagen (CTX-I) according to manufacturer instructions (IDS) and measured on an EZ 




Fluorescence Activated Cell Sorting (FACs) Analysis  
Bone marrow was isolated from the femur via flushing in FACs buffer (1X PBS with 2%FBS, 
0.5mMEDTA), and 106 cells stained with anti-mouse F4/80 (APC, Abcam, A3-1), anti-mouse 
CD68 (FITC, Biolegend, FA-11), anti-mouse CD11b (APC, Biolegend, M1/70), anti-mouse Gr-1 
(FITC, Biolegend, RB6-8C5), and/or anti-mouse Ly6G (FITC, Biolegend, 1A8). Isotype controls 




Tibiae were harvested from 6, 16 and 22wk old mice and fixed in 10% NBF for 24-48hrs at 4°C, 
then stored in 70% ethanol. Tibiae were scanned by micro-computed tomography at a 12µm 
voxel size (Scanco µCT-100) as previously described [20] and following established guidelines 
[22].  Trabecular bone was measured starting 360μm distal to the top of the proximal growth 
plate and extending 600µm distally with a threshold of 180 mg/cm3. Trabecular bone 
morphometric variables analyzed included bone volume (BV/TV), trabecular number (Tb.N), 
trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp) and trabecular bone mineral density 
(Tb.BMD). Cortical bone was measured starting 3mm proximal to the tibia-fibula junction and 
extended 360μm with a threshold of 280 mg/cm3. Cortical bone morphometric variables 
analyzed included total volume (Tt.V), cortical volume (Ct.V), cortical volume fraction 
(Ct.V/Tt.V), cortical thickness (Ct.Th), and bone mineral density (BMD).  
 
TUNEL Staining 
Spleens and tibiae were fixed in 10% NBF for 24-48hrs at 4°C. Tibiae were decalcified in 14% 
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EDTA for 10-14 days. Spleens and tibiae were processed, embedded in paraffin, and sectioned at 
5μm. Sections were stained for terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) positive cells (In Situ Cell Death Detection Kit, TMR red, Roche). TUNEL positive 
cells were quantified in the white pulp of the spleen and in the bone marrow of 22wk old WT 
and KO mice. 
 
Static Histomorphometry 
Tibiae were fixed in 10% NBF for 24-48hrs at 4°C, decalcified in 14% EDTA for 10-14 days, 
embedded in paraffin, and sectioned at 5μm.  A central slice of the proximal tibiae was stained 
with hematoxylin and eosin (H&E) or tartrate resistant acid phosphatase (TRAP, Sigma 387A) 
and bone morphometry or osteoclast quantification performed as described [23] and according to 
standards set by the ASBMR [24]. The ROI was manually defined, beginning 200µm distal to 
the proximal growth plate and extending 1200µm distally.    
 
Dynamic Histomorphometry 
Five and two days prior to sacrifice, mice were administered calcein (Sigma Aldrich, 30mg/kg, 
IP). Tibiae were harvested and fixed in 10% NBF for 24-48hrs and stored in 70% ethanol. 
Undecalcified tibiae were embedded in methylmethacrylate, sectioned (8μm), and dual-labeled 
surfaces quantified as previously described [25]. Bone formation rate (BFR/BS) and mineral 
apposition rate (MAR) were analyzed. 
 
In vitro osteoblast mineralization assays 
Calvarial osteoblasts were isolated from day 4-10 old KO and WT mice, expanded and induced 
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to differentiate and mineralize as previously described [26]. RNA was harvested and processed 
using RNeasy Mini Kit (Qiagen). Reverse transcription PCR was conducted, and the cDNA 
products were amplified and detected using TaqMan Universal PCR master mix (Applied 
Biosystems) and TaqMan probes, including mouse bglap (Mm03413826_m1), runx2 
(Mm00501584_m1) and mouse actb (Mm02619580_g1) as an endogenous control. Realtime 
PCR was analyzed on ABI PRISM 7700 (AppliedBiosystems).  
 
Bone marrow stromal cells (BMSCs) were obtained from flushing bone marrows of 6 and 22wk 
old KO and WT mice with plain α-MEM, centrifuging and resuspending with α-MEM medium 
(20% FBS, Pen/Strep, glutamine) containing 10nM dexamethasone (Sigma). BMSCs were 
seeded at 2 x 105 cells/well in 24-well plates, grown to confluency, and treated with β-
glycerophosphate and ascorbic acid to induce mineralization. Cells were fixed and stained using 
the von Kossa method to assess mineralized nodules at day 7, 14, and 21 [27].  
 
In vitro osteoclast assays 
Bone marrow from 6  week old KO or WT mice was extracted into 100mm dishes in complete α-
MEM medium (10% FBS, Pen/Strep, glutamine). The following day, non-attached cells were re-
plated onto petri dishes and treated with murine M-CSF (30ng/mL eBioscience) for 4-5 days. 
Cells were then split with 10µM EDTA in ice cold PBS and re-plated at 60,000/cm2 in 48 or 96 
well plates with M-CSF (30ng/ml) and murine RANKL (50ng/mL) (Peprotech). Osteoclastic 
cells were identified via TRAP staining (Sigma 387A kit) or seeded onto Corning Osteoassay 
plates to measure resorptive functional activity. Osteoclast assays were performed as above using 
bone marrow from 22wk old WT mice. At the time of osteoclast differentiation induction using 
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RANKL, cell cultures were treated with rmMFG-E8 (500ng/mL, R&D Systems) or BSA control 
(500ng/mL, Millipore). Cultures were stained for TRAP and quantified.  
 
Efferocytosis 
Bone marrow macrophages were assessed for efferocytic capacity of apoptotic BMSCs or 
apoptotic thymocytes. Bone marrow from 6 or 22 week old WT or KO mice was harvested and 
cultured in macrophage differentiation media (α-MEM, 10% FBS, Pen/Strep, glutamine, 
30ng/mL M-CSF) for 7 days and replated in 6 well plates at a density of 1.5 x 106/well. BMSCs 
were harvested from 6-8 week old KO and WT mice via bone marrow flush and cultured in α-
MEM medium (20% FBS, Pen/Strep, glutamine) containing 10nM dexamethasone (Sigma). 
BMSCs were grown to confluency, dissociated from tissue culture plate using 0.25% trypsin-
EDTA and resuspended in 1X PBS. BMSCs were stained with CellTrace™ CFSE Cell 
Proliferation Kit (2μM, Invitrogen). Apoptosis was induced by exposure to UV light for 30 min 
and cells recovered at 37°C for 2hrs. The thymus was dissected from 6-10 wk old KO or WT 
mice in ice cold 1X PBS, pressed though a 70μm cell strainer, red blood cells lysed with 1X 
ACK, and resuspended in complete α-MEM plus 0.1μM dexamethasone. Thymocytes were 
incubated at 37°C for 16hrs to induce apoptosis, then stained with pHrodo™ succinimidyl ester 
(SE) (20ng/mL, Invitrogen)[28]. Apoptotic BMSCs and thymocytes were counted via trypan 
blue exclusion and resulted in 80-95% apoptosis. Apoptotic cells (BMSCs or thymocytes) were 
cultured with macrophages at a 1:1 ratio in plain α-MEM for 2 hours, fixed in 1% PFA, stained 
for F4/80-APC (Abcam, A3-1). Efferocytosis was measured via flow cytometric analysis for 





Statistical analyses were performed by unpaired Student's t test to compare two groups or 
ANOVA to compare three or more groups with a significance of p < 0.05. Data are presented as 
mean ± standard error of mean (SEM).   
 
Results 
MFG-E8 deficiency leads to age-associated osteopenia 
The skeletal phenotypes of female MFG-E8 deficient mice were assessed at 6, 16 and 22 
weeks and compared to age matched WT controls. At 6 weeks of age, MFG-E8 and WT mice 
had similar trabecular BV/TV (Figure 4.1A, B) and Ct.V/Tt.V (Figure 4.1C). With age, MFG-
E8 deficient mice had lower bone mass compared to WT, with significantly decreased trabecular 
BV/TV at 22 weeks (Figure 4.1A, B) and significantly reduced cortical bone at 16 and 22 weeks 
(Figure 4.1C). Serum ELISAs of bone formation (Figure 4.1D) and resorptive markers (Figure 
4.1E, F) showed similar trends in KO and WT with age. Serum TRAcP 5b, a marker reflecting 
osteoclastic cells quantitatively in the body, was decreased in MFG-E8 KO mice at 22wks of age 
compared to WT (Figure 4.1E).  In contrast, CTX-I, a marker of osteoclast functional activity 
was increased in MFG-E8 KO mice at 22wks compared to WT controls (Figure 4.1F).  
 
Increased osteoclasts in 22wk KO mice 
Trabecular bone analysis of the tibia confirmed KO mice had statistically decreased 
trabecular BV/TV (-32%, Figure 4.2A), unchanged Tb.Th (-5%, Figure 4.2B), decreased Tb.N 
(-15%, Figure 4.2C), unchanged trabecular spacing (+8%, Figure 4.2D), and decreased 
trabecular BMD (-33%, Figure 4.2E) compared to WT control mice. Cortical volume fraction 
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and cortical thickness were statistically decreased 4% and 9% respectively in KO mice compared 
to WT (Figure 4.2F, G). Dynamic histomorphometry was performed in mice at 22wks age with 
no significant changes observed in bone formation (BFR/BS) or mineral apposition rate (MAR) 
between KO and WT  mice (Figure 4.2 H, I). Osteoclast number (N.Oc/BS) per bone surface 
was increased in 22wk old KO mice compared to WT (Figure 4.2J). These data suggest the 
reduced bone phenotype in 22wk old KO mice is in part due to an increase in osteoclasts. 
 
Loss of MFG-E8 results in altered immunologic profile in spleen and bone marrow  
In order to evaluate the immunologic impact of MFG-E8, spleens were harvested and 
weighed from 22wk old KO and WT mice. KO mice had significantly increased spleen weight 
per body weight compared to WT mice (Figure 4.3A). FACs analysis of bone marrow 
populations revealed KO mice had significantly increased neutrophils (CD11bhiLy6G+, Figure 
4.3B) and myeloid-derived suppressor cells (MDSCs, CD11bhiGr-1+, Figure 4.3C) compared to 
WT. F4/80+ (murine macrophages) and CD68+ (macrophage and dendritic cells) populations 
were not changed in KO mice compared to WT (data not shown). Spleens and tibiae were fixed, 
embedded in paraffin, sectioned and stained for TUNEL positive cells reflecting cell death. 
TUNEL-positive cells were unchanged in the bone marrow of 16 and 22wk old KO and WT 
mice, suggesting apoptotic cells clearance in the marrow may be facilitated via other efferocytic 
pathways (Figure 4.3D). In vitro efferocytosis studies were performed to assess the effect of 
MFG-E8 deficiency on bone marrow macrophage engulfment of apoptotic cells.  No significant 
alterations in engulfment of apoptotic BMSCs or thymocytes were seen in vitro (data not 
shown). Interestingly, TUNEL positive cells were increased in the white pulp of spleens from 
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22wk old KO mice compared to WT (Figure 4.3E) which might explain a site specific 
efferocytic function of MFG-E8. 
 
Impact of MFG-E8 on cellular activity: osteoblastic and osteoclastic cells  
To better understand the cellular contributions to the age-related skeletal phenotype seen 
in the MFG-E8 deficient mice, a series of in vitro assays were performed. Calvarial osteoblasts 
were isolated from 4-10 day old KO or WT mice, expanded and mineralization or gene 
expression analyzed. KO calvarial osteoblast preparations showed increased mineralized nodules 
compared to WT but no changes in runx2 or osteocalcin gene expression were detected (Figure 
4.4A). BMSCs were cultured from 6 and 22 week old WT and KO mice and induced to 
differentiate. BMSCs from 6 week old KO mice  had increased mineralized nodules compared to 
WT mice after 14 days of culture (Figure 4.4B, left). Interestingly, BMSCs from 22 week old 
mice showed the opposite trend. KO BMSCs displayed decreased mineralized nodules compared 
with WT mice at 14 and 21 days of culture (Figure 4.4B, right). In vitro osteoclast assays from 
6 week old mice revealed no significant alterations in osteoclast differentiation or resorptive 
capacity between WT and KO mice (Figure 4.4C). Osteoclasts from 22 week old mice WT were 
cultured with rmMFG-E8 or BSA control, stained for TRAP and quantified. Treatment with 
rmMFG-E8 significantly reduced osteoclast formation and size (Figure 4.4D).   
 
Intermittent PTH treatment leads to robust anabolic response in KO mice 
MFG-E8 KO and WT mice (16 week) were treated daily with iPTH or vehicle for 6 
weeks to evaluate the therapeutic potential of a known anabolic bone agent (Figure 4.5A). All 
data are presented as treatment (PTH) over control (vehicle). PTH increased spleen weight in 
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both WT and KO mice (tx/control > 1.0, Figure 4.5B). PTH did not alter the CD11bhiLy6G+ 
populations in WT and KO mice whereas PTH  increased marrow CD11bhiGr-1+ cells in WT but 
not KO mice (Figure 4.5C). Complete blood counts from mice WT and KO treated with vehicle 
or PTH  showed PTH treatment decreased the percent neutrophils in the peripheral blood in both 
WT and KO treated mice (Table 4.1). Red blood cell MCV and MCH were significantly 
increased in KO mice compared to WT mice, and PTH further increased these parameters in KO 
mice (Table 4.1). 
 Adult mice treated with vehicle or PTH were assessed for skeletal phenotypes. Static 
histomorphometry of tibia showed an anabolic response in both WT and KO mice in the 
proximal tibia (Figure 4.5D). Trabecular bone analysis of the tibia via μCT showed both WT 
and KO mice responded to iPTH treatment (tx/control > 1.0, Figure 4.5 E-H). KO mice showed 
a stronger anabolic response to PTH in BV/TV (Figure 4.5E), Tb.N (Figure 4.5G) and Tb.BMD 
(Figure 4.3H) than PTH treated WT mice. KO and WT had similar cortical bone anabolic 
responses to PTH (Figure 4.5I, J).  
Mertk is an efferocytic receptor on macrophages. MFG-E8/Mertk double KO (dKO) mice 
were generated to assess the effect of further decreasing a different efferocytic pathway. The 
resulting phenotype was similar in the dKO mice as the MFG-E8KO phenotype. Double KO 
mice had decreased bone with age (Figure 4.7A, B) and responded to iPTH treatment to a 
greater extent than WT controls (Figure 4.7C). These data suggest Mertk deficiency does not 
lead to a stronger phenotype than MFG-E8 deficiency alone.   
 
KO mice display increased osteoclasts per surface, rescued by PTH treatment 
The serum formation marker P1NP and serum resorptive markers TRAcP 5b and CTX-I 
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were all increased with iPTH treatment in both KO and WT mice (Figure 4.6A-C). The increase 
in serum P1NP was larger in iPTH treated KO than WT mice (Figure 4.6A). Bone formation 
(BFR/BS) and mineral apposition rate (MAR) were increased in both iPTH treated WT and KO 
mice, but KO mice showed a lower response in dynamic bone formation parameters with iPTH 
treatment versus WT (Figure 4.6D,E). The increase in osteoclast number (N.Oc/BS) per bone 




 MFG-E8 is a known anti-inflammatory mediator. It is well accepted that chronic 
inflammation increases during the aging process leading to the upregulation of pro-inflammatory 
mediators. Chronic increases in inflammatory cytokines are seen in post-menopausal 
osteoporosis, a disease whose pathology is related to increased osteoclast differentiation and 
activity [29]. The current study describes the contributions of MFG-E8 in the aging skeleton. 
MFG-E8 deficient mice developed a skeletal phenotype that became apparent with age. At 16 
weeks of age, MFG-E8 KO mice showed a trend of decreased trabecular bone and significantly 
decreased cortical bone compared to WT and displayed significantly decreased trabecular and 
cortical bone at 22 weeks of age. These data suggest that MFG-E8 is a contributor to bone 
turnover in adult bone. Interestingly, a previous report of MFG-E8 contributions to bone showed 
decreased vertebral trabecular bone volume fraction in MFG-E8 deficient mice as early as 6 
weeks of age [15], and may describe a location specific effect. The difference of onset of 
osteopenic phenotype between these two models may also represent differences in the 
development of the genetic knockouts. The genetic model presented here was developed by 
 89 
 
inserting the pGT1-pfs gene trap vector in intron 7 of Mfge8, leading to protein degradation [2]. 
Sinningen et al. [15] used a KO model that was generated by replacing exons 2 to 6 of Mfge8 
with a neomycin resistance cassette [30]. This suggests that disrupting the proper transcription of 
the gene may result in a more dramatic phenotype present at an earlier age whereas the 
prevention of protein secretion results in a phenotype that becomes apparent with time.  
Interestingly, while male mice did have a reduction in trabecular BV/TV at 22wks of age 
(data not shown), the phenotype was more dramatic in female mice. Sinningen et al. [15] also 
saw a reduced bone phenotype in female mice, suggesting a possible sex-specific phenotype 
which should be further explored; however information about a male phenotype was not 
discussed. Given that MFG-E8 is highly expressed in mammary gland tissue and is important in 
mammary gland development and involution [2], it may be associated with hormonal controls 
related to sex steroids that in turn impact a gender specific effect on the skeleton.  
The reduced bone phenotype in MFG-E8 KO mice has been attributed to increased 
osteoclast numbers; via not clearly delineated mechanisms [17]. In concert with an osteoclastic 
phenotype, administration of recombinant MFG-E8 protein to inflammation-induced periodontal 
bone defects decreased bone loss [17]. An inflammatory phenotype was not previously detailed 
in the bones of MFG-E8 deficient mice. Given the relationship between inflammation and 
osteoclast activation, we aimed to identify if the reduced bone phenotype in MFG-E8 deficient 
mice was due in part to an enhanced inflammatory environment. Adult MFG-E8 KO mouse 
spleen weights were increased and bone marrow neutrophils and MDSCs were increased, which 
is consistent with increased inflammatory phenotype. These data are consistent with previous 
findings that MFG-E8 KO mice have increased spleen size at 40 weeks of age [7] and display 
signs of inflammation in other tissues [13].  In the present study, MFG-E8 KO mice showed 
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increased osteoclast number per bone surface and increased serum CTX-I levels consistent with 
an inflammatory induced osteoclastogenesis. Proinflammatory cytokines increase osteoclastic 
differentiation and activity via upregulation of RANKL [31]. Increased proinflammatory 
cytokine production has been associated with systemic and/or local bone loss in patients with 
inflammatory diseases [32, 33] including systemic lupus erythematous (SLE) [34], rheumatoid 
arthritis [35-37], inflammatory bowel disease [38, 39], and periodontal disease[40]. Recombinant 
MFG-E8 protein decreased osteoclast differentiation suggesting that MFG-E8 signaling directly 
affects pathways important to osteoclast differentiation and may be a potential targeted treatment 
for inflammatory bone loss. These findings are similar to recently published articles detailing the 
contributions of MFG-E8 to osteoclast differentiation and function [15-17], and extends these 
findings into an adult mouse model. 
A distinct function of MFG-E8 is to act as a bridge between apoptotic cells and 
phagocytes to facilitate engulfment of dead cells [6]. Accumulations of apoptotic cells lead to 
increased pro-inflammatory cytokine production. Polymorphisms of MFG-E8 have been found 
in cases of SLE, which is characterized by decreased apoptotic cell clearance as well as 
decreased bone mass [41]. The efferocytic capacity of bone marrow macrophages was 
unchanged in vitro in MFG-E8 deficient mice. TUNEL positive cell populations trended 
downward in the bone marrow and TUNEL staining of spleens, revealed increased apoptotic 
bodies in the white pulp of the spleen. This phenotype, consistent with previous literature [7], 
suggests that in vivo there is an alteration in apoptotic cell clearance in MFG-E8 deficient mice. 
The increase in TUNEL positive cells in MFG-E8 deficient spleens but not so in the bone 
marrow suggests compensatory efferocytic mechanisms may be more operative and critical in 
the bone marrow environment. Alternatively, the data presented here may also suggest MFG-E8 
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is more dispensable in bone in regards to efferocytic clearance of apoptotic cells. However, the 
increase in marrow neutrophils and MDSCs may in fact reflect a reduced efferocytic 
environment in the marrow. Ineffective efferocytosis leads to increased inflammatory cytokines 
that support the increase in these cells [42]. Further understanding of the pathways which are 
most important in the marrow space will help delineate if and how the process of apoptotic cell 
clearance regulates bone turnover.  
MFG-E8 deficiency resulted in increased osteoclasts due to an enhanced inflammatory 
environment. Currently, therapeutic interventions for patients with inflammatory bone loss 
include anti-resorptives such as bisphosphonates as well as anti-inflammatory targeted therapies.  
Intermittent PTH administration has been extensively studied for its anabolic effects in bone. It is 
FDA approved but is limited to use in cases of severe osteoporosis. Better understanding of 
phenotypes in which PTH may be a beneficial therapeutic could lead to more targeted use of the 
anabolic agent as well as the latest anabolic agent abaloparatide which interacts with the same 
receptor at PTH [43]. In adult MFG-E8 KO mice, PTH was an effective therapeutic and 
surprisingly resulted in a larger anabolic response in KO versus WT mice. Additionally, iPTH 
treatment decreased the number of osteoclasts per bone surface in the adult KO mice and brought 
osteoclast numbers to the level of WT vehicle mice. Treatment with iPTH has been shown to 
both decrease peripheral neutrophils [20] as well as polymorphonuclear leukocyte infiltration in 
healing oral tissue [44]. In our model, iPTH treatment similarly decreased peripheral neutrophil 
numbers. These data suggest iPTH therapy may alter the inflammatory phenotype and be 
beneficial in treatment bone loss due to inflammation. PTH increases specialized pro-resolving 
factors in the bone marrow including resolvin D1, D2 and lipoxins suggesting iPTH therapy aids 
the resolution of inflammation [45]. A previous study of the application of iPTH in a model of 
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rheumatoid arthritis showed PTH repaired local erosions [46] and a clinical trial of local PTH 
application to periodontal defects showed enhanced bone regeneration in PTH treated lesions 
[47]. Collectively, these data suggest PTH may be a particularly effective therapeutic in certain 
types of inflammatory bone disease, yet future studies are necessary to confirm its therapeutic 
benefit  and further delineate mechanisms. 
 In conclusion, our data show that MFG-E8 deficiency leads to an altered immunologic 
profile in the bone marrow, is associated with bone loss with age, and is responsive to 















Figure 4.1. MFG-E8 KO mice have reduced bone mass with age. Tibiae harvested from 6, 16, 
and 22wk old MFG-E8 KO and WT female mice were analyzed for trabecular BV/TV (A, B) 
and cortical volume per total volume (Ct.V/Tt.V) (C) by μCT. (D) Serum formation marker 
P1NP and serum resorptive markers TRAcP 5b and CTX-I were measured via ELISA at the time 










Figure 4.2. Adult (22wk) KO mice have reduced bone mass and increased osteoclast 
numbers. (A-E) Tibiae were harvested from female 22 week old WT and KO mice and 
trabecular parameters quantified via μCT. KO mice displayed significantly reduced trabecular 
BV/TV (A), Tb.N (C), and Tb.BMD (E). Trabecular thickness (B) and trabecular spacing (D) 
were not significantly different in WT and KO mice. (F, G) Cortical bone was measured in the 
midshaft of the tibia of 22 week old WT and KO mice. KO mice had reduced Ct.V/Tt.V (F) and 
Ct.Th (G) compared to WT control mice. (H, I) Mice were administered calcein (30mg/g, I.P.) 5 
and 2 days prior to sacrifice. Dynamic histomorphometric analyses were performed in the 
cancellous bone of the proximal tibia. Sections were analyzed for bone formation rate (BFR/BS) 
and mineral apposition rate (MAR). No significant differences were seen between WT and KO 
mice. (J) Paraffin embedded tibiae were sectioned and stained for TRAP. TRAP+ multinucleated 
osteoclasts were quantified per bone surface (N.Oc/BS). Adult KO mice had increased N.Oc/BS 
compared to WT controls. Representative images on right. n=6-11/group, *p<0.05, **p<0.01, 







Figure 4.3. Adult KO mice have increased spleen size and greater numbers of marrow 
neutrophils and myeloid cells. (A) Spleens were harvested at time of sacrifice, weighed and 
compared to body weight. Spleen weight per body weight was increased in 22 week old KO 
versus WT mice. n=10-11/group, *p<0.05, ***p<0.001, data are ± SEM. (B, C) Marrow was 
flushed from femora of 22wk old WT and KO mice and stained for flow cytometric analysis of 
CD11bhiLy6G+ (neutrophils) and CD11bhiGr-1+ (immature myeloid cells) populations. KO mice 
displayed significantly increased CD11bhiLy6G+ and CD11bhiGr-1+ cells compared to WT. n=6-
8/group, *p<0.05, ***p<0.001, data is mean ± SEM. (D , E) Tibiae and spleens were processed, 




















Figure 4.4. Aged KO BMSCs had decreased mineralization. (A) Calvarial osteoblasts were 
cultured from day 4-10 old KO and WT mice, expanded and induced to differentiate and 
mineralize. KO calvarial osteoblasts displayed increased mineralization. Runx2 and bglap 
expression were measured at day 7 of differentiation and no changes were observed. (B) BMSCs 
were cultured from 6 and 22wk mice, induced to differentiate toward osteoblasts, and 
mineralized nodules measured via von Kossa staining. Six week KO BMSCs had similar 
mineralization to WT at d7 and d21 of culture with increased mineralization at d14. Twenty-two 
wk KO BMSCs showed decreased mineralization at d14 and d21 compared to WT. 
Representative von Kossa stained wells from 6 and 22wk WT and KO BMSCs (d14). n=4-
5/group, **p<0.01, data is ± SEM. (C) Osteoclasts were derived from 6wk old KO and WT 
mice. Osteoclast differentiation and resorptive activity were unchanged between WT and KO. 
(D) Osteoclasts were derived from 22wk old mice and treated with BSA or rmMFG-E8 
(500ng/mL). Osteoclasts were stained for TRAP. Treatment with rmMFG-E8 significantly 







Figure 4.5. Anabolic response to iPTH is greater in adult KO mice than WT. (A) 
Experimental design. KO and WT mice (16wks) were administered daily injections of PTH 
(50μg/kg, SC) or vehicle (0.9% saline) for 6 weeks and sacrificed at age 22wks to assess spleen 
and marrow phenotypes. (B) Spleens were harvested from vehicle and PTH treated KO and WT 
mice and weighed. PTH treatment similarly increased spleen weight per body weight in both WT 
and KO mice (tx/control > 1.0). (C) Marrow flow cytometric analysis for CD11bhiLy6G+ and 
CD11bhiGr-1+ populations showed that PTH treatment of WT mice resulted in increased 
CD11bhiGr-1+ populations (tx/control > 1.0) but no change was seen in PTH treated KO 
compared to vehicle treatment (tx/control ~1.0). (D) H&E stained paraffin sections of KO and 
WT tibiae treated with PTH or vehicle were quantified for bone area per total area. Both WT and 
KO mice had an anabolic response to PTH treatment (tx/control > 1.0). (E) Trabecular BV/TV 
analysis of proximal tibia via μCT. Both KO and WT displayed significantly increased BV/TV 
with PTH treatment. PTH treatment showed a greater anabolic effect in KO mice compared to 






Figure 4.6. Bone formation and resorption analyses in PTH and vehicle treated KO and 
WT mice. (A, B, C) Serum was collected at time of sacrifice and P1NP, TRAcP 5b, and CTX-I 
were measured via ELISA. n=10-11/group, *p<0.05, **p<0.01, ***p<0.001, data is ± SEM. (D, 
E) Calcein (30mg/g, I.P.) was administered 5 and 2 days prior to sacrifice. Undecalcificed tibiae 
were collected, fixed, embedded, and sections were analyzed for bone formation rate (BFR/BS) 
and mineral apposition rate (MAR). iPTH treatment increased BFR/BS and MAR in both KO 
and WT (tx/control >1.0) but to a greater extent in the WT mice compared to KO. (F) TRAP 
stained paraffin embedded tibiae sections were quantified for TRAP positive multinucleated 
cells. KO mice treated with iPTH showed decreased osteoclast number/bone surface (N.Oc/BS) 



















Figure 4.7. Double MFG-E8/Mertk KO mice display a similar phenotype to MFG-E8 KO 
mice. To assess any additive effects of Mertk KO in our MFG-E8 mice, a double MFG-
E8/Mertk KO (dKO) mouse was generated. (A,B) WT and dKO mice had similar trabecular 
bone at 6 and 16 weeks, and a trend of decreased bone in dKO mice at 22 wks of age. (C) 
Sixteen wk old WT and dKO were treated with vehicle or iPTH daily for 6 weeks and skeletal 
phenotypes assessed. WT and dKO mice had anabolic responses to iPTH treatment, and the dKO 
anabolic response exceeded the response in WT mice. n=7-10/group, *p<0.05, **p<0.01, data 

















Table 4.1. Complete blood counts.  
 
WBC = white blood cell, NE = neutrophil, LY = lymphocyte, MO = monocyte, EO = eosinophil, 
BA = basophil, RBC = red blood cell, HB = hemoglobin, HCT = hematocrit, MCV = mean 
corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular 
hemoglobin concentration, RDW = red cell distribution width, PLT = platelet, MPV = mean 
platelet volume  
Data are expressed as mean ± SEM 
ap<0.05 vs. WT Vehicle, bp<0.01 vs. WT Vehicle, cp<0.05 vs. KO Vehicle, dp<0.01 vs. KO 
Vehicle, ep<0.001 vs. KO Vehicle 
  WT Vehicle WT PTH KO Vehicle KO PTH 
  n=10 n=11 n=10 n=10 
      
WBC K/uL 4.7 ± 0.5 5.9 ± 0.6 4.7 ± 0.3 6.1 ± 0.6 
NE# K/uL 0.85 ± 0.10 0.91 ± 0.13 0.98 ± 0.11 0.96 ± 0.12 
LY# K/uL 3.7 ± 0.4 4.8 ± 0.4 3.6 ± 0.3 5.0 ± 0.5c 
MO# K/uL 0.09 ± 0.01 0.11 ± 0.01 0.10 ± 0.02 0.10 ± 0.02 
EO# K/uL 0.03 ± 0.01 0.07 ± 0.02 0.05 ± 0.04 0.04 ± 0.01 
BA# K/uL 0.01 ± 0.004 0.03 ± 0.008 0.02 ± 0.01 0.01 ± 0.003 
      
NE% % 18.1 ± 1.1 15.0 ± 0.9a 20.4 ± 1.4 15.5 ± 1.0c 
LY% % 79.0 ± 1.3 81.7 ± 1.1 76.3 ± 2.1 82.1 ± 1.0c 
MO% % 1.9 ± 0.3 2.0 ± 0.2 1.9 ± 0.2 1.7 ± 0.04 
EO% % 0.65 ± 0.20 0.95 ± 0.29 0.95 ± 0.59 0.58 ± 0.18 
BA% % 0.27 ± 0.06 0.38 ± 0.12 0.37 ± 0.20 0.14 ± 0.04 
      
RBC M/uL 8.8 ± 0.1 8.5 ± 0.2 8.7 ± 0.1 7.8 ± 0.3c 
HB g/dL 13.1 ± 0.2 12.7 ± 0.2 13.3 ± 0.1 12.3 ± 0.5 
HCT % 44.8 ± 0.9 43.9 ± 0.9 46.9 ± 0.7 43.0 ± 1.8 
MCV fL 50.8 ± 0.7 51.5 ± 0.5 53.9 ± 0.2b 55.2 ± 0.3d 
MCH Pg 14.8 ± 0.2 15.0 ± 0.2 15.3 ± 0.1a 15.8 ± 0.1c 
MCHC g/dL 29.2 ± 0.3 29.1 ± 0.3 28.4 ± 0.3 28.5 ± 0.2 
RDW % 17.1 ± 0.7 18.2 ± 0.1 16.0 ± 0.1 17.2 ± 0.1e 
      
PLT K/uL 747 ± 16 746 ± 22 744 ± 27 752 ± 14 
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INCREASED TOOTH EXTRACTION SOCKET BONE FILL WITH CLODRONATE-
LOADED LIPOSOME TREATMENT 
 
Abstract 
Ineffective oral wound healing is detrimental to patients’ oral health related quality of 
life. Delineating the cellular mechanisms involved in optimal healing will elicit better 
approaches to treating patients with compromised healing. Osteal macrophages have recently 
emerged as important positive regulators of bone turnover. The contributions of macrophages to 
long bone healing have been studied but their role in oral osseous wound healing following tooth 
extraction are less appreciated. Clodronate-loaded liposomes were used a tool to deplete 
phagocytic macrophages and assess oral osseous bone fill after extraction. In addition to 
macrophage depletion, off target osteoclast depletion occurred. Interestingly, depletion of 
macrophages and osteoclasts via clodronate treatment had different effects based on the location 
and type of bone turnover. In the tibiae, clodronate treatment drastically increased trabecular 
bone volume fraction after 7 and 14 days of treatment, which correlated with increased CD68+ 
cells and decreased F4/80+ cells in the marrow. In extraction sockets, clodronate treatment had 
no effect on bone fill at 7 days after surgery but increased extraction socket bone fill 14 days 
after surgery. This increase was to a much lesser extent than the large changes seen in 
homeostatic bone turnover in the long bone. These data suggest a temporal and spatial specificity 




Compromised wound healing in the oral cavity leads to prolonged infection, pain and 
overall decreased quality of life. Proper healing of bony defects in the oral cavity from tooth 
extractions, periodontal procedures, congenital diseases or due to surgical reconstruction is 
crucial to restoring function. Compromised immune systems, radiation therapy or IV 
bisphosphonate cancer therapies can lead to ineffective bone healing in the jaw, causing chronic 
issues such as osteonecrosis [1]. Having a better understanding of the mechanisms of osseous 
wound healing will help to abrogate the issues seen in these inadequate healing states, and aid in 
the design of successful therapeutic strategies. 
Extraction sockets are unique locations for healing as they require both bony and soft 
tissue healing and are exposed to the oral flora. Several cell types are crucial to the osseous 
healing of extraction sockets including traditional bone cells (osteoclasts, osteoblasts and 
osteocytes) and immune cells such as macrophages and neutrophils [2]. Soft tissue closure 
requires the coordination of fibroblasts and epithelial cells, along with immune cells aiding in 
tissue repair. Understanding the individual roles of each cell in the healing response will aid in 
creating targeted therapies to assist in the healing process.  
Clodronate-loaded liposomes have been extensively studied for their effectiveness as a 
macrophage-ablation tool [3]. Clodronate bisphosphonate is encapsulated into liposomes which 
are readily engulfed by phagocytic cells. Once engulfed, the phagocytic cell machinery degrades 
the liposome and releases clodronate. Clodronate then is converted to a non-hydrolizable 
analogue of ATP resulting apoptosis of the cell which engulfed the liposomes. Mice treated with 
clodronate-loaded liposomes have depleted macrophages in several tissues in the body, including 
the bone marrow of the long bones [4, 5]. The knowledge of the impact of clodronate-loaded 
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liposomes or oral osseous wound healing is lacking. The aim of this study was to delineate the 
role of macrophages in oral wound healing of extraction sockets via clodronate treatment.  
   
Materials/Methods 
Animals 
All mice were maintained in accordance with institutional animal care and use guidelines, and 
experimental protocols were approved by the Institutional Animal Care and Use Committee of 
the University of Michigan. Six week old male C57BL6/J mice were ordered from Jackson 
Laboratories. Mice were anesthetized with ketamine/xylazine (90mg/kg (K), 5mg/kg (X), IP). 
Once adequate anesthesia was achieved, the mandible was retracted and left and right maxillary 
M1 molars extracted. Mice were given a dose of buprenorphine (0.05-1.0 mg/kg, SC) at time of 
surgery and every 8-12 hours for 48 hours following surgery. PBS- or clodronate-loaded 
liposomes (clodronateliposomes.com) were administered locally in extraction sockets at time of 
surgery as well as daily intraperitoneal injections at a dose of 10μL/g from day 0-6 and 6μL/g 
from day 7-13. Mice were euthanized at day 7 or 14 following tooth extraction and tissues 
harvested for analysis.  
 
Serum ELISAs 
Blood was harvested at time of euthanasia via intracardiac puncture under anesthesia 
(ketamine/xylazine), allowed to coagulate for at least one hour at room temperature, spun down 
at 8000 rpm for 10 minutes, and liquid serum collected.  Samples were stored at -80°C until use. 
Enzyme immunoassays were used to measure the serum concentrations of tartrate-resistant acid 
phosphatase form 5b (TRAcP 5b) and propeptide of type I procollagen (P1NP) according to 
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manufacturer instructions (IDS) and measured with an EZ Read 400 microplate reader with 
Galapagos software (Biochrom US, Holliston, MA). 
 
Fluorescence Activated Cell Sorting (FACs) Analysis  
Bone marrow was isolated from the tibia via flushing in FACs buffer (1X PBS with 2%FBS, 
0.5mM EDTA), red blood cells lysed with 1x ACK, and 106 cells stained with anti-mouse F4/80 
(APC, Abcam, A3-1), anti-mouse CD68 (FITC, Biolegend, FA-11), and anti-mouse CD206 
(FITC, Biolegend, C068C2). Isotype controls were used to confirm antibody specificity. FACs 
analysis was performed using a BD FACs Aria II (BD Biosciences). 
 
MicroCT (μCT) 
Tibiae and maxillae were harvested at time of sacrifice (7 or 14 days) and fixed in 10% neutral 
buffered formalin for 24-48hrs at 4°C, then stored in 70% ethanol. Samples were scanned by 
micro-computed tomography at a 12µm voxel size (Scanco µCT-100) as previously described 
[6] and following established guidelines [7]. Tibial trabecular bone volume of interest was 
defined as starting 360μm distal to the top of the proximal growth plate and extended 600µm 
distally. A threshold of 180 mg/cm3 was used for trabecular analysis. Extraction socket bone fill 
was measured in mesial, distal and palatal extraction sockets. Trabecular bone parameters 
analyzed included trabecular bone volume fraction (Tb. BV/TV), trabecular number (Tb.N), 
trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp) and trabecular tissue mineral density 
(Tb.TMD). Tibial cortical bone volume of interest included a region of the midshaft of the tibia 
starting 3mm proximal to the tibia-fibula junction and extending 360μm distally. The cortical 
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bone threshold was 280 mg/cm3. Cortical bone morphometric variables analyzed included 
cortical volume fraction (Ct.V/Tt.V) and cortical thickness (Ct.Th).  
 
Histomorphometry 
Maxillae and tibiae were fixed in 10% neutral buffered formalin for 24-48hrs at 4°C, decalcified 
in 14% EDTA for 10-20 days, embedded in paraffin, and sectioned at 5μm.  A transverse section 
of the maxilla was cut to view bilateral extraction sockets and stained with hematoxylin and 
eosin (H&E), tartrate resistant acid phosphatase (TRAP, Sigma 387A), or F4/80 (antibody 
information). F4/80 immunohistochemical staining was performed following previously 
published protocols [8, 9]. Briefly, slides were de-paraffinized in xylene and rehydrated in 
ethanol series. Slides were then treated with H2O2 (3% in TBS) for 10 minutes at room 
temperature, washed in TBS, then digested in sodium citrate (10mM, pH 6.0) which was brought 
up to 71-75°C then cooled to room temperature overnight. Slides were washed, serum blocked 
with BioCare Background Sniper for 15 minutes, and incubated with anti-F4/80 (abcam 6640, 
clone CI:A3, diluted 1/350 in BioCare Da Vinci Green diluent) for 1.5 hours at room 
temperature. Slides were washed with TBS then incubated with goat anti-rat secondary antibody 
for 30 min at room temperature, followed by SA-HRP incubation and DAB chromogen. Slides 
were counterstained with hematoxylin and dehydrated before coverslip. Tibial sections were 
stained with hematoxylin and eosin (H&E) or tartrate resistant acid phosphatase (TRAP, Sigma 
387A). Osteoclast quantification in tibiae and extraction sockets was performed as described [4] 






Statistical analyses were performed by unpaired Student's t test to compare PBS-liposome versus 
clodronate-liposome treatments at each timepoint with a significance of p < 0.05. Data are 
presented as mean ± standard deviation (SD).   
 
Results 
Clodronate loaded liposomes deplete bone marrow F4/80+ macrophages 
Maxillary M1 molars were extracted bilaterally and mice were treated with a one-time 
intra-defect application of clodronate (CLOD)- or PBS-loaded liposomes in addition to daily 
intraperitoneal injections of clodronate- or control PBS-loaded liposomes (Figure 5.1). 
Treatment with clodronate loaded liposomes resulted in body weight reductions compared to 
PBS-loaded liposomes after 7 days of treatment, whereas no changes were seen at 14 days 
(Figure 5.2A). Spleen weights were reduced in clodronate treated mice at both 7 and 14 days of 
treatment (Figure 5.2B). Flow cytometric analysis of long bone marrow showed clodronate 
treatment decreased F4/80+ macrophages and M2-like (F4/80-CD206+) macrophages (Figure 
5.2C-D). In contrast, CD68hi cell populations were increased with clodronate treatment 
compared to control PBS (Figure 5.2E). 
 
Bone fill following tooth extraction was increased in clodronate loaded liposome treated mice 
Maxillary M1 molars were extracted and extraction sockets were analyzed for bone fill at 
7 and 14 days post-surgery using micro-CT analysis. Clodronate treatment had no effect on 
trabecular bone parameters after 7 days of treatment (Figure 5.3A-F), with the exception of 
trabecular tissue mineral density (TMD), which was significantly decreased with clodronate 
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treatment. After 14 days of daily treatment with clodronate- or PBS-loaded liposomes, 
clodronate treated mice had increased extraction socket BV/TV compared to PBS treated mice 
(Figure 5.3G,M). Given that trabecular number was decreased with clodronate treatment 
(Figure 5.3H), the increase in trabecular bone volume fraction with clodronate treatment was 
due to an increase in trabecular thickness (Figure 5.3I). The increase in bone volume suggests 
clodronate depleted cells which are negative regulators of bone fill following tooth extraction. 
Alternatively, upregulated cell types may be positive regulators. The significant increase in 
CD68 positive cells in the long bone suggests these may be positive regulators of bone turnover 
and oral osseous repair.  
 
Clodronate treated mice have increased tibial trabecular bone associated with decreased 
resorption 
 In addition to assessing the effects of clodronate treatment on maxillary extraction socket 
healing, systemic skeletal effects were determined. Clodronate treatment resulted in dramatic 
increases in trabecular bone in the proximal tibia as early as 7 days after treatment, and further 
increased trabecular bone after 14 days (Figure 5.4A-F,J). Trabecular bone tissue mineral 
density was decreased with clodronate treatment (Figure 5.4E), which suggests that although 
there was increased bone, the average density of the bone in the clodronate treated mice was 
lower than that in PBS treated. Cortical bone was unchanged in clodronate treated mice at both 
time points (Figure 5.4G). The serum formation marker P1NP and to an even greater extent, the 
serum resorptive marker TRAcP 5b were significantly reduced in clodronate treated mice at 7 
and 14 days (Figure 5.4H-I). Osteoclasts are known phagocytes and have the ability to engulf 
foreign material (i.e. liposomes). Given the reduction in serum TRAcP 5b, the increased bone 
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phenotype may be largely due to alterations in osteoclast number and/or activity. To further 
assess the effect of clodronate on osteoclasts, we measured TRAP+ cells in tibial histology 
sections. Clodronate treatment decreased TRAP+ osteoclasts in tibiae sections (Figure 5.4K). 
The reduction in formation marker P1NP may be due to a coupling response in which decreased 
osteoclast signaling feeds back to decrease osteoblast formation and activity. Alternatively and 
potentially in addition to the coupling response, the reduction in bone formation could be 
attributed to the reduction in macrophages. TRAP+ osteoclasts and F4/80+ macrophages were 
assessed in extraction sockets of mice treated with PBS- or clodronate-loaded liposomes.  
 
Treatment with clodronate-loaded liposomes decreased F4/80+ and TRAP+ cells in the bone 
 Mice treated with clodronate- or PBS-loaded liposomes were assessed for TRAP+ 
(osteoclasts) and F4/80+ (macrophages) cells in the maxillary extraction sockets at 7 and 14 days 
after surgery. TRAP+ (purple) multinucleated osteoclasts increased in extraction sockets at 14 
days compared to 7 days in both PBS and clodronate treated mice (Figure 5.5). There was a 
decrease in TRAP+ osteoclasts at both 7 and 14 days after extraction in the clodronate treated 
mice compared to PBS. F4/80 is a marker for murine macrophages. F4/80+ (brown) cells were 
present in the marrow at both 7 and 14 days after extraction and were decreased with clodronate 
treatment relative to PBS (Figure 5.6).  
 
Clodronate treatment did not affect non-wounded oral bone volume 
 Given the changes seen in steady state long tibiae bone volume and extraction socket 
bone fill, non-wounded bone in the maxilla was analyzed to determine the effects of clodronate 
on bone in other oral sites. Trabecular bone volume was measured between the maxillary M2 and 
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M3 molars (Figure 5.7, right). No significant differences were seen in non-wounded oral bone 
volume after 14 days of treatment with clodronate-loaded liposomes (Figure 5.7, left), 
suggesting a site-specific effect. Table 5.1 summarizes the effects of clodronate on bone volume, 
TRAP+ osteoclasts, F4/80+ macrophages, and CD68+ macrophages in the tibia and maxilla.  
 
  Discussion 
Macrophages are positive regulators of bone turnover, yet the mechanisms by which they 
exert these effects are currently unknown. The macrophage depletion model clodronate-loaded 
liposomes, results in F4/80-positive macrophage cell depletion in several tissues including the 
lung, liver, spleen and bone marrow [4, 5, 11, 12]. Interestingly, a subset of bone marrow 
macrophages and dendritic cells positive for the marker CD68 are increased in clodronate-treated 
mice, consistent with previous studies [4]. Given the large influx of apoptotic cells from the 
induction of phagocytic cell death by clodronate, it is hypothesized that CD68-positive cell 
populations are increased to aid in the clearance of apoptotic cell bodies via some type of 
feedback mechanism.  
It was previously shown that macrophages secrete osteogenic factors during the process 
of apoptotic cell clearance (termed efferocytosis) [13]. In this study as well as others, mice 
treated with clodronate-loaded liposomes had increased bone volume in the appendicular 
skeleton [4, 5], suggesting the increase of CD68+ cells may contribute positivity to bone 
turnover. Widespread depletion of monocytes/macrophages including CD68+ and F4/80+ cells 
using the MAFIA mouse model results in overall decreased bone volume [4, 8, 12, 14, 15]. 
These contrasting phenotypes in which CD68+ cells are high (in clodronate) and low (in 
MAFIA) suggest that CD68+ macrophage populations are positive regulators of bone 
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homeostasis compared to the F4/80+ population. It is important to note, however, that osteoclasts 
were also decreased with clodronate-loaded liposome treatment. Given that osteoclasts are 
mediators of bone resorption, decreasing their numbers undoubtedly decreases resorption and 
may lead to increased bone volume. Targeted depletion of macrophage population subsets to rule 
out osteoclast effects can aid in delineating the contributions of each cell type to homeostatic 
bone turnover as well as healing.   
Mice treated with clodronate-loaded liposomes had significantly increased trabecular 
bone in the tibiae. The trabecular bone volume fraction was increased 81% and 152% compared 
to PBS treatment at days 7 and 14, respectively. Alternatively, while oral extraction socket bone 
fill was significantly increased at day 14 following surgery, the increase in bone was only 7%. 
This suggests that macrophage and osteoclast depletion via clodronate-loaded liposomes has site 
specific effects as well as effects on healing versus homeostatic turnover. Clodronate-liposome 
treatment has been investigated in the context of long bone injury healing. Treatment with 
clodronate-loaded liposomes significantly decreased new bone formation in a tibial injury model 
[12, 16] and in femoral fracture healing [17, 18], further supporting site specific responses to 
clodronate treatment. To better understand how the changes seen in extraction socket bone fill 
are mediated, it is helpful to understand the sequence of events in extraction socket healing.  
After a tooth is extracted a well-orchestrated series of inflammatory and healing events 
occurs. In mice, immediately after the tooth is removed, a clot forms [2]. Early in healing of a 
mouse extraction socket (d0-5), inflammatory cells and MSCs migrate and proliferate. Around 
day 3 after extraction, fibroblasts proliferate and osteoblasts differentiate to aid in collagen 
synthesis and bone formation, respectively. The levels of inflammatory cells and fibroblasts peak 
at around day 7 and osteoblasts peak at day 14 [2]. Blood vessels begin to form around day 5 and 
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continue to increase until day 21. Osteoclasts differentiate and begin to remodel the new bone 
around day 14. This sequence of events leads to a rapid increase in bone tissue from day 5 to 14 
at which time bone fill levels off as osteoclast remodeling takes over. Our findings are consistent 
with the published literature where control mice had a clear increase in TRAP+ osteoclasts in 
extraction sockets at day 14 compared to day 7. While clodronate-loaded liposomes decreased 
osteoclasts in extraction sockets at both time points, the effect of depleting osteoclasts may not 
be appreciated until later time points. The difference in extraction socket bone fill may instead be 
due to an increase in CD68+ cells as was seen in the bone marrow. Future studies should include 
temporal depletion of macrophages and osteoclasts via clodronate-loaded liposomes, including 
before and/or after tooth extraction surgery. 
The location specific changes seen with clodronate are outlined in Table 5.1, and 
highlight the difference between the response in the tibia and maxilla. These differences 
observed in the long bone site versus the oral cavity may be due to many factors including 
differences in the cell populations in the marrow in these sites, origin of these cells, mechanical 
stimulation and exposure to different environmental cues. Bone marrow stromal cells (BMSCs) 
from the mandible have been shown to differentiate and mineralize more than BMSCs from long 
bone sites [19, 20]. Additionally, osteoclasts from the mandible and tibia have similar resorptive 
activity, but osteoclasts from the mandible differentiate faster than those from the long bone [21-
23]. These findings support the differences seen in the oral wound healing sites compared to long 
bone sites. Furthermore, although these cells look similar histologically [24], they arise from 
different origins during embryonic development. The bones of the mandible and maxilla arise 
from neural crest cells of the neuroectoderm layer, and long bones arise from the mesoderm [25]. 
Also, the mandible and maxilla undergo intramembranous ossification compared to 
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endochondral ossification of the long bones [26]. Lastly, the bones in the jaws are exposed to 
stronger forces during mastication than those generated during walking [27, 28], and mechanical 
stimulation is an important regulator of bone turnover.  
Interestingly, we observed a decrease in tissue mineral density (TMD) in the tibiae and 
extraction socket with clodronate-loaded liposome treatment. One factor that could drive this 
change in TMD is a difference in the rate of mineralization. While clodronate liposomes may not 
directly interact with the mineralization process in a significant way, they did inhibit 
macrophages which have a known role in regulating bone mineralization [8, 12, 15, 29]. 
Specifically, macrophages have been shown to secrete osteogenic factors such as TGF-β1 [13], 
oncostatin M [30-32] and BMP-2 [33], which could impact mineralization. In addition to direct 
impacts on the bone mineralization process altering TMD, in a rapidly healing model, TMD is 
also likely to be driven in large part by the average age of the tissue present, or how much time it 
has been mineralized. A bone with a higher average tissue age could be expected to have a 
higher TMD. In our clodronate-treated healing socket, a potential anti-osteoclast effect could 
yield a greater tissue age due to decreased resorption of the aged bone. In extraction sockets, 
TMD was decreased at day 7 with clodronate treatment, suggesting less mineralization. In our 
model, the effect of TMD is likely not singular, but rather the complex result of multiple distinct, 
and even opposing, biological actions that combine to yield observed TMD phenotype.   
It should not be overlooked that clodronate is a bisphosphonate. Bisphosphonates have 
been studied in the context of extraction socket healing due to their potential ability to lead to 
osteonecrotic lesions in the oral cavity. Because bisphosphonates are anti-resorptives, they 
prevent osteoclasts from clearing bone that has been haphazardly formed. Treatment with 
bisphosphonates leading to necrotic bone has been characterized by empty osteocyte lacunae [34, 
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35]. Treatment with clodronate-loaded liposomes did not alter the presence of osteocytes in 
lacunae (data not shown). Additionally, bisphosphonate treatment increases extraction socket 
bone fill [35, 36], but typically to a greater extent than seen in the present study. Although the 
increase in CD68+ macrophages and decrease in osteoclasts explains an overall increase in bone, 
the percent increase with clodronate treatment may be less than that seen with other 
bisphosphonates due to the altering of other macrophage populations, namely the F4/80+ cells. 
In a healing model, decreased F4/80+ cells may compromise the ability of the bisphosphonate to 
increase bone. This may support the hypothesis that specific macrophage subsets have distinct 
and necessary roles in the context of healing. This is supported by data in long bone healing in 
which F4/80+ cell depletion impaired healing [12]. Perhaps, the depletion of the F4/80+ cells 
prevents the clodronate-loaded liposome treatment from reaching the same level of bone fill 
result seen with non-liposome bisphosphonates.  
Clodronate-loaded liposome treatment resulted in increased bone in the tibiae as well as 
increased bone fill in the extraction sockets. The extent to which clodronate exerted its effect on 
bone was variable according to the location and whether the bone was under normal homeostatic 
turnover or if it is was new bone in response to a wound. Macrophage and osteoclast populations 
were altered with clodronate and suggest a crucial balance of these cells to maintain proper oral 
wound healing. In regards to clinical treatment of oral osseous wounds, it is important to 
understand what cell populations may be potential targets to aid in osseous healing without 
compromising the quality of the bone. Further insight into the temporal and spatial specificities 






Figure 5.1. Experimental model. Six week old male C57BL/J mice were anesthetized with 
ketamine and xylaxine, mandible retracted and maxillary M1 molars extracted bilaterally. Mice 
received local delivery of clodronate- or PBS-loaded liposomes in extraction sockets at time of 
surgery. Intraperitoneal injections of clodronate- or PBS-loaded liposomes were given daily at a 
dose of 10μL/g from days 0-6 and 6μL/g days 7-13.  Mice were sacrificed at day 7 or 14 after 
surgery and tissues harvested for serum biomarkers, bone marrow flow cytometric analysis 














Figure 5.2. Clodronate treated mice have decreased spleen weight and altered bone 
marrow macrophage populations. (A) Body weight was measured at the time of sacrifice. 
Clodronate treated mice displayed decreased body weight at 7 days post-extraction surgery and 
mice sacrificed at 14 days after surgery showed no differences in body weight. (B) Spleens were 
harvested at time of sacrifice, weighed and compared to body weight. Spleen weight was 
decreased in clodronate treated mice at both time points. (C-E) Bone marrow was flushed from 
tibiae at time of sacrifice and stained for flow cytometric analysis of F4/80+ (macrophages), 
CD206+ (M2-like macrophages) and CD68hi (monocytes, dendritic cells). Clodronate-loaded 
liposome treated mice displayed decreased F4/80+ and F4/80+/CD206+ and increased CD68hi 
marrow populations compared to PBS-treated mice. n=8-10/group, *p<0.05, **p<0.01, 







Figure 5.3. Clodronate treatment increases extraction socket bone fill at 14 days post tooth 
extraction. Maxillae were harvested at time of sacrifice and analyzed via micro-CT (μCT). (A-
F) Extraction socket bone fill was unchanged after 7 days of treatment with clodronate. (G-L) 
Clodronate liposome treatment significantly increased extraction socket bone fill after 14 days of 
treatment compared to PBS treated mice due to increased trabecular thickness. (M) 
Representative images of bone fill in extraction socket after 14 days of healing. n=8-10/group, 



















Figure 5.4. Clodronate treatment increases tibial trabecular bone.  (A-F) Tibiae were 
harvested at time of sacrifice and trabecular parameters quantified via μCT. Clodronate-loaded 
liposome treated mice had significantly increased trabecular trabecular BV/TV (A), trabecular 
number (Tb.N, B), trabecular thickness (Tb.Th, C) and decreased trabecular spacing (Tb.Sp, D) 
and trabecular tissue mineral density (Tb.TMD, E) at day 7 and 14 compared to PBS treated 
mice. Clodronate treatment increased trabecular bone more at 14 days than at 7 days of 
treatment. (F) Representative images of trabecular bone in proximal tibiae after 14 days of 
treatment with PBS or clodronate. (G) Cortical bone was measured in the midshaft of the tibia 
and was unchanged with clodronate treatment. (H, I) Serum formation (P1NP) and resorptive 
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(TRAcP 5b) markers were measured. Clodronate treatment significantly reduced both formation 
and resorption compared to PBS-treated mice. (J) Representative image of H&E section showing 
increased bone in clodronate treated mice. (K) Tibiae sections were stained for TRAP. 
Clodronate treatment decreased TRAP+ cells in tibiae. n=8-10/group, *p<0.05, **p<0.01, 





























Figure 5.5. Clodronate treatment decreases TRAP+ osteoclasts in extraction sockets. 
TRAP+ multinucleated osteoclasts are increased in extraction sockets at day 14 compared to day 
7 after surgery. Treatment with clodronate-loaded liposomes decreases TRAP+ multinucleated 
















Figure 5.6. F4/80-positive cells are reduced in extraction sockets with clodronate treatment.  
F4/80+ cells are located in the marrow spaces at 7 and 14 days post-extraction and clodronate 















Figure 5.7. Clodronate treatment had no effect on non-wounded oral bone. Interseptal bone 
volume fraction was measured between M2 and M3 molars in the maxilla with no statistically 
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DISCUSSION AND CONCLUSION 
 
Discussion 
 Understanding the specific roles of individual cells in tissue homeostasis is the basis of 
decades of basic science and translational research. The ultimate goal of identifying the 
mechanistic role of cells under normal conditions is to then be able to identify how these roles 
change in disease. New tools can then be developed to manipulate these mechanisms to promote 
a desired outcome. Each tissue is different and houses its own unique cellular profile which 
affects how that tissue functions, what diseases it is susceptible to and how it responds to injury. 
In the context of the skeletal system, there are 2 major organs, the bone and the bone marrow. 
The bone and bone marrow consists of many cells types that must communicate effectively with 
one another to maintain homeostasis. When one cell type in the bone does not function properly, 
the balance of resorption and formation is affected, leading to potentially undesirable outcomes.  
 One particularly influential cell in bone is the macrophage. Macrophages are myeloid 
lineage cells and function as phagocytes. They are immune cells that can exert pro- and anti-
inflammatory functions. When early and late macrophages are depleted using macrophage 
ablation models, bone forming osteoblasts no longer secrete matrix for mineralization, but the 
mechanisms by which macrophages exert these positive effects are not clear. The work presented 
in this dissertation adds to the current literature on bone marrow macrophage function via in 
vitro and in vivo experimental approaches.  
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 A comprehensive review of the current literature on the bone marrow macrophage 
indicates that the pro-resolving nature of macrophages may explain some of their positive effects 
on bone. To better understand the resolving nature of bone marrow macrophages, a series of in 
vitro experiments were performed to identify regulators of macrophage activity, specifically their 
ability to phagocytose dead and dying cells. In non-bone tissues, anti-inflammatory cytokines 
increase macrophage efferocytosis [1, 2]. It was hypothesized that these anti-inflammatory 
proteins exert similar effects on bone marrow macrophages. Interleukin-10 (IL-10) was a 
candidate cytokine to assess efferocytosis of apoptotic bone cells. IL-10  regulates 
osteoclastogenesis and mice deficient in IL-10 have reduced bone mass [3, 4], yet it was unclear 
how IL-10-associated efferocytosis by bone marrow macrophages may contribute to these 
effects. Consistent with our hypothesis, IL-10 treatment increased macrophage uptake of 
apoptotic bone marrow stromal cells (apBMSCs). IL-10 enhanced efferocytosis by shifting 
macrophage polarization toward the pro-resolving M2 phenotype and increasing the M2 
macrophage ability to uptake apoptotic cells. Next, further information was gathered on the 
signaling pathways affected by the treatment of macrophages with IL-10.  Macrophages were 
treated with an inhibitor of STAT3 phosphorylation (Stattic) prior to IL-10 treatment.  This 
significantly reduced efferocytosis of apBMSCs, confirming IL-10 increases efferocytosis and 
M2 polarization in a pSTAT3-dependent manner.  
Efferocytosis of apBMSCs versus neutrophils led to a unique profile of cytokines 
released by the bone marrow macrophages. The cell specific cytokine response may indicate 
what effects efferocytosis has on bone modeling and remodeling. Following efferocytosis of 
apBMSCs, macrophages displayed increased secretion of monocyte chemoattractant protein-
1/CC chemokine ligand 2 (MCP-1/CCL2) and transforming growth factor beta-1 (TGF-β1). 
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CCL2 promotes osteoclastogenesis in part due to the recruitment of monocyte/osteoclast 
precursors [5]. The release of CCL2 by macrophages engulfing apoptotic bone cells may 
increase bone turnover by recruitment of new osteoclasts and bone macrophages. TGF-β1 is a 
known mesenchymal stem cells recruitment factor [6, 7]. Macrophage secretion of TGF-β1 in 
response to apBMSCs cells may contribute to repopulating the bone forming units.   
Together, the data presented in Chapter 3 show one modulator of macrophage efferocytosis of 
apBMSCs and detail two important cytokines which are upregulated in response. While this 
information tells us more about mediators of efferocytosis in bone, in vivo work should be 
performed to confirm the biologic relevance of these findings.   
 The goal of Chapter 4 was to assess the contributions of MFG-E8, a known anti-
inflammatory mediator, to bone turnover. One well established function of MFG-E8 is to bridge 
between dead and dying cells and macrophages to coordinate engulfment of the apoptotic cell. 
Interestingly, bone marrow macrophages deficient in MFG-E8 did not display altered engulfment 
phenotype in vitro. Additionally, TUNEL positive cells were increased in the spleen and slightly 
but not significantly decreased in the marrow of MFG-E8 KO mice compared to controls. This 
suggested that MFG-E8 may not be the predominant regulator of efferocytosis in the bone 
marrow microenvironment. Given the high turnover rate of cells in the marrow, it would not be 
surprising to see other efferocytic mechanisms upregulated to compensate for the lack of MFG-
E8. Additionally, an MFG-E8 homologue, developmental endothelial locus-1 (DEL-1), has been 
shown to function similarly to MFG-E8 and regulates efferocytosis to a larger extent than MFG-
E8 in certain tissues [8, 9]. Measuring the relative MFG-E8 and DEL-1 expression in the bone 
and bone marrow may provide insight on key efferocytic pathways in bone.  Future studies can 
provide further insight into the important regulators of efferocytosis in this highly plastic tissue.  
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While an efferocytic phenotype was not observed in the bone of the MFG-E8 deficient mice, 
other inflammatory phenotypic changes were observed. In addition to its role in apoptotic cell 
clearance, MFG-E8 is an important anti-inflammatory mediator. MFG-E8 has been shown to 
down-regulate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
osteopontin signaling, which are both key regulators of osteoclastic cell differentiation, 
activation and adhesion [10, 11]. Adult MFG-E8 KO mice had increased bone marrow 
neutrophils and myeloid derived suppressor cells as well as increased spleen weights. 
Inflammatory environments have been shown to upregulate osteoclast differentiation and 
activity. Consistent with an increase in osteoclastic bone resorption, MFG-E8 deficient mice 
developed a skeletal phenotype of reduced bone. This phenotype became more apparent with 
age. No phenotype was seen at 6wks of age, but 16wk old mice had decreased cortical bone and 
a trend of decreased trabecular bone. At 22wks, the trabecular phenotype was significant. Other 
groups have also reported on a reduced bone phenotype with MFG-E8 deficiency and found this 
to be consistent with an increase in osteoclast number [12]. In our model, serum from 22wk old 
MFG-E8 KO had increased CTX-I levels which is a marker for osteoclast resorptive activity. In 
vivo, osteoclast number per bone surface was also increased in 22 wk old KO mice compared to 
WT.   
A therapeutic intervention was tested in adult MFG-E8 mice. Intermittent PTH (iPTH) is 
an anabolic bone agent with use limited to severe cases of osteoporosis. Adult MFG-E8 KO mice 
responded robustly to iPTH treatment. Treatment with iPTH decreased osteoclast number per 
bone surface in the adult KO mice and decreased peripheral neutrophil numbers. It is 
hypothesized that iPTH therapy may alter the inflammatory phenotype by mechanisms which 
remain unclear. The insight gained from further studies characterizing the effect of iPTH on 
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inflammation should prove valuable in identifying new patient groups that may benefit from this 
anabolic bone agent as well as the newest anabolic agent, abaloparatide, which utilizes the same 
receptor.  
Steady state bone turnover and bone healing require the presence of macrophages to aid 
in the formation of newly mineralized tissue [13, 14]. Oral osseous wound healing is complicated 
by the unique environment of the oral cavity as well as the need for soft tissue closure. Chapter 5 
delves into the contributions of macrophages and osteoclasts to oral osseous wound healing 
following tooth extraction. Clodronate-loaded liposomes were used to preferentially target 
phagocytic cells and induce apoptosis. Treatment with clodronate-liposomes decreased F4/80+ 
cells in the marrow and in extraction sockets. However, likely due to compensatory mechanism, 
CD68 positive cells were increased in the marrow. CD68 positive cells are mature phagocytic 
macrophages and dendritic cells. This population may be increased to effectively clear the insult 
of apoptotic cell bodies from the clodronate treatment. Additionally, osteoclasts were decreased 
in histologic sections of extraction sockets in mice treated with clodronate and was confirmed by 
decreased serum TRAcP 5b, a marker for osteoclastic bone resorption.  
Mice treated with clodronate displayed location specific alterations in bone volume. In 
the long bones, clodronate dramatically increased trabecular bone volume fraction by 152% after 
14 days of treatment. Alternatively, in extraction sockets, clodronate increased bone fill to a 
much lesser extent; there was an increase in bone fill of 7% compared to PBS treated mice. 
Interestingly, others studies have reported that clodronate-loaded liposome treatment decreased 
new bone formation in a long bone healing [13, 15-17]. Table 6.1 outlines the site-specific 
effects of clodronate treatment as well as MFG-E8 deficiency. As described above, MFG-E8 
deficiency leads to osteopenia in adult mice. Oral osseous wound healing was measured in mice 
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with MFG-E8 deficiency and no alterations to bone fill in extraction sockets or drill hole defects 
were seen (data not shown, summarized in Table 6.1). Because there is an apparent site-specific 
effect of clodronate and MFG-E8 deficiency, it is important to understand the sequence of events 
in tooth extraction socket healing. Briefly, in a mouse extraction socket inflammatory cells 
infiltrate early (d0-3). Osteoblasts form newly mineralized bone around day 5 which is then 
remodeled by osteoclasts after day 7 [18]. In our model, there is a clear increase in TRAP+ 
osteoclasts in extraction socket healing at day 14 compared to day 7, and clodronate decreased 
TRAP+ cells at both time points. Because osteoclast remodeling occurs at or after the latest time 
point measured, the resulting phenotype may not reflect an osteoclast specific outcome. These 
data support macrophages and osteoclasts function at different times to aid in the healing 
process. Future studies should be performed to deplete macrophages and osteoclasts at different 
stages of healing, including before and/or after tooth extraction surgery.  
In addition to depletion of these cells at different stages, the profiles of these cells need to 
be characterized. Previous studies have shown that bone marrow stromal cells (BMSCs) and 
osteoclasts from oral versus long bone sites have different differentiation and activity [19-23]. 
Also, the oral bones and long bones derive from different embryological origins. The mandible 
and maxilla arise from the neuroectoderm layer and undergo intramembranous ossification while 
the long bones arise from the mesoderm and undergo endochondral ossification [24, 25]. Bone 
marrow macrophages from different skeletal sites should also be investigated for their ability to 
differentiate, phagocytose and efferocytose.  Given the oral cavity is unique in its exposure to 
bacteria and pathogens, the macrophages in these sites may be primed to be more active 
phagocytes. Additionally, mechanical forces from mastication are almost double the forces seen 
during walking, and mechanical stimulation positively supports bone formation [26, 27]. The 
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different forces in oral versus long bones may contribute to the relative activity of cells from 
these different skeletal sites. Clearly, more information about how the location of these cells 
affects their behavior is needed.    
Bisphosphonates are anti-resorptive therapeutics that target osteoclasts to prevent 
resorption and further bone loss in patients with osteoporosis. Clodronate is a bisphosphonate 
drug. Treatment of mice with bisphosphonates prior to tooth extraction leads to increased 
extraction socket bone fill [28, 29]. These effects seen with non-liposome bisphosphonates tend 
to lead to a greater increase in extraction socket fill than seen in the clodronate-loaded liposome 
model. Because clodronate-loaded liposomes target macrophages in addition to osteoclasts, this 
may explain the difference between liposome-loaded and non-loaded bisphosphonate extraction 
socket bone fill outcomes. F4/80+ cells are positive regulators of bone turnover [14]. With 
clodronate-loaded liposome treatment, F4/80+ cells are decreased in extraction sockets. The 
clodronate-loaded liposome depletion of F4/80+ cells may therefore negatively impact bone 
formation and explain why clodronate-loaded liposome treatment resulted in differential healing 
than previously published non-liposome bisphosphonate treatments. 
A better understanding of the cell populations crucial to proper healing will lead to the 
development of potential targeted therapies to enhance healing.  
 
Conclusions 
The information gained from these studies has the potential to positively affect patient 
care. Understanding the link between efferocytosis, inflammation and bone volume can lead to 
new screening methods to detect individuals susceptible to inflammation-induced osteoporosis. 
For example, the data presented in Chapter 4 suggests that screening for polymorphisms in the 
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gene encoding MFG-E8 or measuring serum MFG-E8 levels may identify patients at risk of 
developing reduced bone volume. Additionally, other studies have investigated the effect of 
recombinant MFG-E8 protein to decrease the severity of inflammation-induced bone loss with 
promising results [12]. Future studies are needed to investigate MFG-E8 as a drugable target. 
Furthermore, an FDA approved anabolic bone agent, iPTH, was highly effective at increasing 
bone in MFG-E8 deficient mice. This suggests iPTH may be useful in treating patients with 
inflammatory bone loss. Clearly, more studies need to be conducted to assess the effects of iPTH 
in other models of inflammation-induced osteoporosis.  
Compromised oral wound healing leads to decreased oral health related quality of life. It 
is important to understand what cell populations may be potential targets to aid in osseous 
healing without compromising the quality of the bone. Further insight into the temporal and 
spatial specificities of osteal macrophages will ultimately lead to better methods to target cells 
important in the healing process of oral wounds. More information in the quality of the bone that 
is produced by treatment with clodronate-loaded liposomes as well as how timing of depletion of 
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